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CHAPTER I 
 
INTRODUCTION 
 
 A wide variety of pharmaceuticals has been approved for use in the United States 
and throughout the world. These drugs are used to treat a number of maladies and 
afflictions, ranging from psychological disorders to cancer to bacterial infections. Some 
of these drugs are compounds that were found in nature and have a long history of use 
that pre-dates modern medicine. Many newer pharmaceuticals are either modified 
versions of compounds isolated from living organisms or were fully synthesized in the 
laboratory with the goal of identifying a compound with a specific bioactivity. Regardless 
of their origins, the mechanism(s) of action of many older drugs is not well understood. 
Quinolones are a class of synthetic antibacterials that fall into this category. Although 
their target enzymes – the bacterial type II topoisomerases, gyrase and topoisomerase IV 
– were discovered fourteen1 and twenty-eight2 years, respectively, after the first member 
of the class was introduced into the clinic,3 much remains unknown about quinolone-
topoisomerase interactions and the molecular mechanism(s) of quinolone action and 
resistance. 
 
Quinolones 
 Nalidixic acid (which is actually a naphthyridine; Figure 1) is the founding 
member of the quinolone class of antibacterials and was one of the first completely 
synthetic antibacterials to be developed.4 It was isolated as a byproduct of the synthesis 
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Figure 1. Quinolone structures. Nalidixic acid is the founding member of the quinolone 
class of antibacterials. Oxolinic acid, pipemidic acid, and cinoxacin are other first 
generation quinolones. Norfloxacin, ciprofloxacin, and ofloxacin are the most relevant 
second-generation quinolones. Levofloxacin (the levorotary isomer of ofloxacin) and 
moxifloxacin are newer generation quinolones. 
3 
 
of chloroquine (an antimalarial) in 1962 by George Lesher and colleagues.5 Nalidixic 
acid was introduced into the clinic in the 1960s for the treatment of uncomplicated 
urinary tract infections caused by enteric bacteria.3 By the 1970s, several additional first-
generation quinolones, including oxolinic acid, pipemidic acid, and cinoxacin, had been 
synthesized and introduced into the clinic (Figure 1).3,4,6-8 
 In the early 1980s, a second generation of quinolones was developed.3,4,6-8 These 
newer drugs spurred the transformation of the quinolones from a little-used drug class to 
the clinical mainstays that they are today. The second generation quinolones, highlighted 
by norfloxacin, ciprofloxacin, and ofloxacin, displayed considerably improved activity 
against gyrase, greater penetration into Gram-positive organisms, and enhanced 
pharmacokinetics and pharmacodynamics. The structural features that facilitated the 
improved activities were the introduction of a fluorine at the C6 position and a ring 
substituent (piperazine or methyl-piperazine) at C7 of the quinolone core (Figure 1).3,4,6-8 
Because of the inclusion of the fluorine, quinolones are often referred to as 
“fluoroquinolones.” 
 Norfloxacin is considered to be the first broad-spectrum quinolone and was 
utilized to a far greater extent than nalidixic acid.3,4,6-8 However, due to low serum levels 
and poor tissue penetration, norfloxacin was still restricted to the treatment of urinary 
tract infections and sexually transmitted diseases. Ciprofloxacin was the first quinolone 
that displayed significant activity outside of the urinary tract.3,4,6-8 After more than twenty 
years in clinical use, ciprofloxacin remains one of the most commonly prescribed 
antibacterial drugs and is used to treat a variety of Gram-negative and, to a lesser extent, 
Gram-positive infections.3,4,7,8 
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 The clinical success of ciprofloxacin spawned an array of newer generation 
quinolones that displayed even greater broad-spectrum activity, especially against Gram-
positive respiratory tract infections. A number of these drugs have been approved for 
clinical use, with levofloxacin and moxifloxacin being two of the most important (Figure 
1). The clinical success of levofloxacin can be partly attributed to its pharmacokinetics – 
treatment requires only a single pill per day.7,9,10 
 A number of diseases are currently treated with quinolones, including urinary 
tract infections and pyelonephritis, sexually transmitted diseases, prostatitis, skin and 
tissue infections, chronic bronchitis, community-acquired and nosocomial pneumonia, 
and intra-abdominal and pelvic infections.11 Quinolones are also important in the 
treatment of multi-drug resistant tuberculosis, and moxifloxacin is in clinical trials as a 
front-line treatment for the disease.12-16 
 
Bacterial Type II Topoisomerases 
 Nearly all species of bacteria encode two distinct (but homologous) type II 
topoisomerases, gyrase and topoisomerase IV.17-23 Both of these enzymes are essential to 
the survival of bacterial cells. They play critical roles in most nucleic acid processes, help 
control levels of DNA under- and overwinding, and remove knots and tangles from the 
bacterial chromosome. Gyrase and topoisomerase IV modulate the topological state of 
DNA by passing an intact double helix through a transient double-stranded break that 
they generate in a separate segment of DNA.  
 The catalytic cycle of type II topoisomerases can be separated into six discrete 
steps (Figure 2). The enzyme begins by binding to DNA at helix-helix crossovers and 
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Figure 2. Catalytic cycle of type II topoisomerases. Step 1: The enzyme binds at helix-
helix crossovers and bends the gate-, or G-, segment of DNA in the presence of divalent 
metal ions (the physiological ion is Mg2+). Step 2: The enzyme cleaves and covalently 
attaches to the newly generated 5’-termini of the G-segment, generating the cleavage 
complex. Step 3: The enzyme hydrolyzes one molecule of ATP in order to pass the 
transfer-, or T-, segment of DNA through the cut it generated in the G-segment. Step 4: 
The enzyme religates the G-segment. Step 5: Upon hydrolysis of a second ATP molecule, 
the T-segment is released from the enzyme. Step 6: The enzyme releases the G-segment 
and resets for another round of catalysis. 
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sampling the genetic material for malleability. If the DNA is sufficiently flexible, the 
enzyme introduces an ~150° bend into the gate- (or G-) segment. The topoisomerase then 
cleaves and covalently attaches to the newly generated 5’-termini of the G-segment. 
Next, the transfer-segment (also called the T-segment) of DNA is passed through the 
double-stranded break in the G-segment. Following strand passage, the enzyme religates 
the DNA break that it created, releases both segments of DNA, and resets for another 
round of catalysis. Divalent metal ions (the physiological ion is Mg2+) are required 
cofactors for DNA bending and the cleavage and religation reactions, and ATP binding 
and hydrolysis are required to drive progression through the catalytic cycle.17-23 
 The DNA cleavage and religation reactions, which constitute the core of 
topoisomerase function, utilize a non-canonical two-metal-ion mechanism.24-26 Gyrase 
and topoisomerase IV generate staggered cuts in the DNA backbone that are 4-bp apart 
and on opposite strands (leaving a 5’-overhang). In order to maintain genomic integrity 
during this process, the enzymes form covalent bonds between active site tyrosine 
residues and the newly generated 5’-DNA termini.17-19,22 These covalent enzyme-cleaved 
DNA complexes are known as “cleavage complexes” (Figure 2). 
 Both gyrase and topoisomerase IV are comprised of two distinct functional 
subunits and function as A2B2 heterotetramers (Figure 3).17,19,22,23 The subunits in gyrase 
are GyrA and GyrB. In Gram-negative species, the genes encoding topoisomerase IV 
subunits were named as partitioning genes, while in Gram-positive species, they were 
named as gyrase-like genes.17,19,27,28 Therefore, in topoisomerase IV, ParC (in Gram-
negative species) and GrlA (in Gram-positive species) are equivalent to GyrA, and ParE 
and GrlB are equivalent to GyrB. The A subunit contains the active site tyrosine residue. 
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Figure 3. Domain structures of type II topoisomerases. Gyrase and topoisomerase IV are 
heterotetrameric enzymes consisting of two A subunits and two B subunits. The A 
subunits (blue and red; GyrA in gyrase and ParC/GrlA in Gram-negative/Gram-positive 
topoisomerase IV) contain the active site tyrosine residue that covalently attaches to the 
newly generated 5’-termini of DNA during the cleavage reaction. The C-terminal 
domains (CTD; red) of the A subunits are variable and allow gyrase to introduce negative 
supercoils into DNA. The B subunits (green; GyrB in gyrase and ParE/GrlB in Gram-
negative/Gram-positive topoisomerase IV) contain the ATPase and TOPRIM domains, 
the latter of which binds the catalytic divalent metal ions essential for enzyme activity. 
Human topoisomerase IIα is homologous to the bacterial type II enzymes. However, 
during the course of evolution, the A and B subunits fused into a single polypeptide 
chain. Therefore, eukaryotic type II topoisomerases function as homodimers. A 
representation of the three-dimensional structure of type II topoisomerases is shown at 
the bottom. 
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The B subunit contains the ATPase domain as well as the TOPRIM domain, which binds 
the divalent metal ions involved in DNA cleavage and religation. Although there is strong 
sequence similarity between gyrase and topoisomerase IV, the C-termini of the A 
subunits are not well conserved. This portion of the protein is involved in topology 
recognition and allows gyrase, but not topoisomerase IV, to generate supercoils in 
DNA.17,19,22,29-31 
 Despite their mechanistic and structural similarities, gyrase and topoisomerase IV 
have separate physiological functions.17,19,22,23 Gyrase is the only type II topoisomerase 
that can actively introduce negative supercoils into DNA. Consequently, the enzyme 
works in conjunction with the omega protein (a type I topoisomerase) to set the 
superhelical density of the bacterial chromosome. In addition, gyrase is primarily 
responsible for removing the torsional stress that accumulates in front of replication forks 
and transcription complexes.17,19,22,23 
 Topoisomerase IV appears to play a lesser role than gyrase in maintaining 
chromosomal superhelical density and alleviating torsional stress. Its major function is 
decatenating daughter chromosomes following replication and removing knots and 
tangles that accumulate in the bacterial chromosome as a result of fundamental cellular 
processes.17,19,22,32,33 
 
Gyrase and Topoisomerase IV as Quinolone Targets 
 In order to carry out their critical physiological functions, gyrase and 
topoisomerase IV generate double-stranded breaks in the bacterial chromosome. Thus, 
while essential for cell survival, these enzymes have the potential to fragment the 
9 
 
genome.17-19,22,23,34 Quinolones take advantage of this latter, and potentially lethal, 
characteristic and kill cells by increasing the concentration of enzyme-DNA cleavage 
complexes.4,18,35-39 Thus, they are referred to as “topoisomerase poisons” because they 
convert gyrase and topoisomerase IV into cellular toxins.35 In contrast, “catalytic 
inhibitors” block the overall catalytic functions of these enzymes without increasing 
levels of DNA strand breaks.  
 Quinolones bind non-covalently to gyrase and topoisomerase IV at the enzyme-
DNA interface in the cleavage-religation active site.40-43 Binding of the drugs in the 
cleavage complex is facilitated by interactions with both the protein and the DNA. 
Because quinolones insert into the DNA at both cleaved scissile bonds in an intercalative 
manner, they increase the steady-state concentration of cleavage complexes by acting as 
physical blocks to religation (Figure 4). Two drug molecules are required to increase 
levels of double-stranded DNA breaks because the scissile bonds on each strand are 
staggered.4,18,36-39 
 When replication forks, transcription complexes, or other DNA tracking systems 
collide with drug-stabilized gyrase- or topoisomerase IV-DNA cleavage complexes, these 
complexes are converted to permanent chromosomal breaks. The generation and 
accumulation of these DNA breaks trigger the SOS response and other DNA repair 
pathways. If the strand breaks overwhelm these processes, they can lead to cell death. 
This is the primary mechanism by which quinolones kill bacterial cells (Figure 5).4,18,36-39 
 Because quinolones stabilize cleavage complexes by inhibiting DNA religation, 
they also impair the overall catalytic functions of gyrase and topoisomerase IV. Thus, in 
addition to acting as poisons, quinolones can act as catalytic inhibitors. The 
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Figure 4. Crystal structure of a moxifloxacin-stabilized Acinetobacter baumannii 
topoisomerase IV-DNA cleavage complex. The catalytic core of the enzyme is shown. 
Moxifloxacin is shown in red, the topoisomerase IV A and B subunits are shown in blue 
and green, respectively, and DNA is shown in yellow. Top: A top view of the cleavage 
complex showing two quinolone molecules intercalating four base pairs apart at the sites 
of DNA cleavage. Bottom: A front view (rotated by 90° from the top view) of the 
cleavage complex. Protein Data Bank accession 2XKK was visualized using Discovery 
Studio 3.5 Visualizer (Accelrys Software Inc.). Adapted from Wohlkonig et al.43 
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Figure 5. Bacterial type II topoisomerases are essential but potentially toxic enzymes. 
The balance between enzyme-mediated DNA cleavage and religation is critical for cell 
survival. If the level of gyrase-mediated DNA cleavage decreases, rates of DNA 
replication slow and impair cell growth (left). If the level of topoisomerase IV-mediated 
DNA cleavage decreases, cells are not able to untangle daughter chromosomes and 
ultimately die of mitotic failure (left). If the level of gyrase- or topoisomerase IV-
mediated DNA cleavage becomes too high (right), the actions of DNA tracking systems 
can convert these transient complexes to permanent double-stranded breaks. The 
resulting DNA breaks initiate the SOS response and other DNA repair pathways and can 
lead to cell death. 
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accompanying loss of enzyme activity affects a number of nucleic acid processes and 
likely contributes to the overall toxicity of these drugs (Figure 5).4,18,36-39 
 Both gyrase and topoisomerase IV are physiologically relevant targets for 
quinolones. Gyrase was first identified as the cellular target of quinolones in 1977,44,45 
fifteen years after the introduction of these drugs into the clinic.3 The later discovery (in 
1990) of topoisomerase IV2 raised the question of whether this enzyme is also a target of 
the quinolones. Based on an analysis of the minimum inhibitory concentration (MIC) of 
Escherichia coli strains carrying drug resistance mutations in gyrase, topoisomerase IV, 
or both enzymes, it was concluded that gyrase is the primary target for quinolones and 
that topoisomerase IV is a secondary drug target.46 Consistent with this conclusion, 
quinolones are more potent against E. coli gyrase than topoisomerase IV46 in vitro and 
induce higher levels of gyrase-DNA cleavage complexes in cells.47 
 Surprisingly, genetic studies in Streptococcus pneumoniae indicated that 
topoisomerase IV, rather than gyrase, was the primary cellular target for ciprofloxacin.48 
This led to the concept that gyrase is the primary target for quinolones in Gram-negative 
bacteria but that the opposite is true in Gram-positive species. However, subsequent 
studies (based on identifying which type II topoisomerase mutated first upon the 
treatment of bacterial cultures with quinolones) found that this paradigm does not hold in 
many cases. There are examples of Gram-positive bacteria in which gyrase is the primary 
target for quinolones. Furthermore, in a given bacterial species, different quinolones have 
been shown to have different primary targets.49-51 Ultimately, the issue of quinolone 
targeting is still a matter of debate and the relative contributions of gyrase vs. 
13 
 
topoisomerase IV to quinolone action needs to be evaluated on a species-by-species and 
drug-by-drug basis. 
 
Quinolone Resistance 
 Quinolone resistance has been steadily increasing since the 1990s.11,52 This rise in 
resistance is threatening the clinical efficacy of the quinolones and has been observed in 
every bacterial species that is treated with this drug class.8,11,39 A number of different 
quinolone resistance mechanisms have been reported and can be grouped into three 
categories: chromosome-mediated, plasmid-mediated, and target-mediated (Figure 6). 
The cellular alterations associated with each mechanism are not mutually exclusive and 
can accumulate to create strains that exhibit very high levels of quinolone resistance. 
 
Chromosome-mediated Quinolone Resistance 
 The cellular concentration of quinolones is regulated by the opposing actions of 
diffusion-mediated drug uptake and pump-mediated efflux. In contrast to Gram-positive 
species, the outer membrane of Gram-negative bacteria poses an additional barrier that 
drugs must cross in order to enter the cell. Therefore, drug influx in Gram-negative 
species is facilitated by protein channels called porins. If the expression of porins is 
downregulated, it can lead to low-level resistance to quinolones (Figure 6).4,52-55 
 Enhanced expression of chromosome-encoded efflux pumps can also lead to 
quinolone resistance (Figure 6). Most commonly, the upregulation of these pumps is 
caused by mutations in regulatory proteins.52,55,56 In general, changes in quinolone uptake 
and retention cause only low-level resistance and, in the absence of additional resistance 
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Figure 6. Mechanisms of quinolone resistance. 1. Chromosome-mediated resistance. 1a) 
Under-expression of porins in Gram-negative species decreases drug uptake. 1b) Over-
expression of chromosome-encoded efflux pumps decreases drug retention in the cell. 2: 
Plasmid-mediated resistance. 2a) Qnr proteins (yellow) decrease topoisomerase-DNA 
binding and protect enzyme-DNA complexes from quinolones. 2b) Aac(6’)-Ib-cr is an 
aminoglycoside acetyltransferase that acetylates the free nitrogen on the C7 ring of 
ciprofloxacin and norfloxacin, decreasing their effectiveness. 2c) Plasmid-encoded efflux 
pumps decrease the concentration of quinolones in the cell. 3: Target-mediated 
resistance. Mutations in gyrase and topoisomerase IV decrease quinolone-enzyme 
interactions. 
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mechanisms, do not appear to be a major clinical issue.56 However, lowering the cellular 
concentration of quinolones creates a favorable background for other forms of resistance 
to develop and propagate.57-59 In addition, these cellular changes can confer low levels of 
resistance to other antibacterial agents as these drugs also enter bacterial cells via 
diffusion and many efflux pumps are multi-drug and, thus, can eliminate a range of 
antibacterials from cells.52,56 
 
Plasmid-mediated Quinolone Resistance 
 Recently, plasmids that carry quinolone resistance genes have been identified as 
an emerging clinical problem (Figure 6). Although the plasmid-encoded genes generally 
cause low-level (≤10-fold) resistance,39,54,55,58-64 changes in quinolone sensitivity as high 
as ~250-fold has been reported.39,54,55 Unlike chromosome-mediated resistance (and 
target-mediated resistance, discussed below), which is transmitted vertically from 
generation to generation, plasmid-mediated quinolone resistance can be transmitted 
horizontally (through bacterial conjugation) as well as vertically. Notably, plasmids that 
confer quinolone resistance typically carry additional genes that can cause resistance to 
other drug classes.54,55,58,62 
 Three families of genes are associated with plasmid-mediated quinolone 
resistance. The first are the Qnr genes, which encode small (~200 amino acid) 
pentapeptide repeat proteins.54,55,65,66 Approximately 100 Qnr variants have been 
identified to date and have been classified into at least five distinct sub-families.55,63,67,68 
These proteins share homology with McbG and MfpA, which are DNA mimics.54,55,65 
The Qnr proteins appear to confer quinolone resistance by two different mechanisms. 
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Like McbG and MfpA, they decrease the binding of gyrase and topoisomerase IV to 
DNA. Thus, they protect cells from quinolones by lowering the number of available 
enzyme targets on the chromosome. They also bind to gyrase and topoisomerase IV and 
inhibit quinolones from entering cleavage complexes formed by the enzymes.65,66,69,70 
 The second plasmid-encoded protein associated with quinolone resistance is 
aac(6’)-Ib-cr.71,72 This protein is a variant of an aminoglycoside acetyltransferase that 
contains two specific point mutations, W102R and D179Y. This enzyme acetylates the 
unsubstituted nitrogen of the C7 piperazine ring of norfloxacin and ciprofloxacin, which 
decreases drug activity. Although both the wild-type and mutant aminoglycoside 
acetyltransferases are capable of acetylating other drugs, only the mutant enzyme is 
active against quinolones.71,72 
 The third group of plasmid-encoded quinolone resistance proteins is comprised of 
efflux pumps (that are distinct from those that are typically encoded on the bacterial 
chromosome). Thus far, three have been identified: OqxAB, QepA1, and QepA2.55,73,74 
Whereas the latter two proteins have been found in human bacterial infections, OqxAB is 
seen almost exclusively in animal infections.55,75,76 
 
Target-mediated Quinolone Resistance 
 The most common form of quinolone resistance consists of point mutations in the 
target enzymes gyrase and topoisomerase IV (Figure 6). Generally, mutation of one type 
II enzyme confers ≤10-fold drug resistance. Selection for higher levels of resistance (~10- 
to 100-fold) usually yields strains with mutations in both enzymes.18,36,37,39,49,77 Although 
mutations have been mapped throughout the A and B subunits of both gyrase and 
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topoisomerase IV in quinolone-resistant strains, the most commonly mutated amino acids 
are a specific, highly conserved serine residue (Ser83 by E. coli GyrA numbering) and an 
acidic residue that is located four positions downstream of the serine (Figure 
7).18,36,37,39,49,77-83 Typically, in both laboratory and clinical isolates, alterations at the 
serine comprise >90% of the mutant pool, with changes at the acidic residue comprising 
the bulk of the other mutations.77,80-85 
 The fact that specific mutations in gyrase and topoisomerase IV cause quinolone 
resistance strongly suggests that drug-protein interactions play an important role in 
stabilizing cleavage complexes. Thus, it has been assumed that these two amino acid 
residues play an integral role in mediating quinolone-enzyme interactions. 
 Recently, four crystal structures of quinolone-stabilized gyrase or topoisomerase 
IV cleavage complexes have been reported that shed light on quinolone-enzyme 
interactions.40-43 Initial structures showed the quinolone bound to the enzyme near the 
serine and acidic resides, but the amino acids were not in close enough proximity to 
mediate drug binding.40-42 However, a later structure captured a quinolone complex that 
contained a non-catalytic Mg2+ ion that was chelated by the C3/C4 keto acid of the drug 
(Figure 7).43 The metal ion was coordinated by four water molecules, and two of these 
water molecules were shown to be stabilized by hydrogen bonds with the side chains of 
the highly conserved serine and acidic residues. Based on this structure and an earlier 
study that suggested a role for metal ions in quinolone action,86 the authors suggested that 
this water-metal ion interaction “bridged” the drug to the enzyme and could account for 
why mutation of these residues results in quinolone resistance.43 
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Figure 7. A water-metal ion bridge is proposed to facilitate quinolone-topoisomerase 
binding. Left: Crystal structure of a moxifloxacin-stabilized A. baumannii topoisomerase 
IV-DNA cleavage complex. Moxifloxacin is shown in black and the non-catalytic Mg2+ 
ion that is chelated by the C3/C4 keto acid of the quinolone and participates in the bridge 
interaction is shown in green. The four water molecules that fill out the coordination 
sphere of the Mg2+ ion are shown in blue. The backbone of selected portions of the 
protein amino acid chain is shown in yellow. The side chains of the serine and acidic 
residues that form hydrogen bonds with the water molecules in the water-metal ion 
bridge are shown in red. For clarity, DNA has been omitted from the picture. Protein 
Data Bank accession 2XKK was visualized using Discovery Studio 3.5 Visualizer 
(Accelrys Software Inc.). Adapted from Wohlkonig et al.43 Right: Simplified diagram of 
the water-metal ion bridge. A generic quinolone is depicted in black, the non-catalytic 
Mg2+ is orange, water molecules are blue, and the coordinating serine and acidic residues 
(B. anthracis topoisomerase IV numbering) are red and green, respectively. Blue dashed 
lines indicate the octahedral coordination sphere of the divalent metal ion. The red or 
green dashed lines represent hydrogen bonds between the serine side chain hydroxyl 
group or the acidic residue side chain carboxyl group and the water molecules. Bottom: 
Sequence alignment of the A subunits showing the serine and acidic residues (red) that 
coordinate the water-metal ion bridge. Sequences of A. baumannii (Ab), Bacillus 
anthracis (Ba), E. coli (Ec), Staphylococcus aureus (Sa), and S. pneumoniae (Sp) gyrase 
(GyrA) and topoisomerase IV (ParC/GrlA) are shown. The homologous regions of 
human topoisomerase IIα (hTIIα) and IIβ (hTIIβ), which lack the residues necessary to 
coordinate the water-metal ion bridge interaction, are shown for comparison. 
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Quinolones and Human Type II Topoisomerases 
 Like bacteria, humans also express two type II topoisomerases, topoisomerase IIα 
and topoisomerase IIβ.19,22,23,28,34 Both the α and β isoforms share significant amino acid 
sequence similarity with the bacterial enzymes. However, during the course of evolution, 
the genes encoding the A and B subunits fused, resulting in a single polypeptide chain 
(Figure 3). Consequently, the human type II enzymes function as homodimers.19,22,28  
 Topoisomerase IIα is essential to human cells, and its level of expression 
oscillates with the cell cycle.22,34 Topoisomerase IIβ is essential during neuronal 
development, but appears to be dispensable once this development is complete. Unlike 
the α isoform, topoisomerase IIβ is expressed at a constant level throughout the cell 
cycle.22,34 Both enzymes function through the same catalytic cycle described above for 
gyrase and topoisomerase IV (Figure 2) and maintain the genome by removing supercoils 
from the DNA, resolving knots and tangles that are introduced into the genome during 
normal cellular processes, and unlinking daughter chromosomes.22,34 
 The human type II topoisomerases are targeted by various anticancer 
chemotherapeutics, including etoposide, doxorubicin, and amsacrine (Figure 8). Similar 
to the quinolones, these drugs act as poisons, stabilizing cleavage complexes and 
inducing cell death by causing an accumulation of chromosome breaks that overwhelm 
DNA repair processes.22,34 Although the clinically relevant quinolones do not display any 
appreciable activity against human type II topoisomerases, some experimental 
quinolones, including CP-115,953 and CP-115,955 (Pfizer), have high activity against the 
human (and bacterial) enzymes (Figure 8).87-90 The basis for the discrimination between 
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Figure 8. Structures of drugs that target human type II topoisomerases. Etoposide, 
doxorubicin, and amsacrine are important anticancer drugs. CP-115,953 and CP-115,955 
are experimental quinolones that have high activity against both human and bacterial type 
II topoisomerases. Ciprofloxacin (a clinically relevant quinolone that is not active against 
human type II enzymes) is shown for comparison.  
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human and bacterial topoisomerases by the clinically relevant quinolones and the dual 
targeting of the enzymes by some experimental quinolones is not known. 
 
Scope of the Dissertation 
 Due to the clinical significance of the quinolone class of antibacterials and the 
increasing prevalence of resistance that extends to every species of bacteria treated with 
these drugs, it is important to define and understand the molecular mechanisms of 
quinolone action and resistance. Therefore, the goals of this dissertation are to: further 
define quinolone-topoisomerase interactions in order to shed on light how quinolones 
stabilize cleavage complexes and inhibit religation; determine how mutations in gyrase 
and topoisomerase IV cause quinolone resistance; establish a basis for the discrimination 
between bacterial and human type II enzymes by clinically relevant quinolones and for 
the dual targeting of these enzymes by some experimental quinolones; and outline the 
roles of quinolone substituents so that this knowledge may used in designing new 
quinolones or quinolone-like drugs that overcome resistance without cross-reacting with 
the human system or that specifically target the human enzymes for potential use as 
anticancer chemotherapeutics. 
 An introduction to bacterial and human type II topoisomerases and the quinolone 
antibacterials is described in Chapter I. The materials and methods used in this 
dissertation are described in Chapter II. 
 Chapter III describes the characterization of the enzymatic activities of wild-type 
and quinolone-resistant mutant topoisomerase IV enzymes from Bacillus anthracis. 
Portions of these findings have been published91,92 and demonstrate that mutations that 
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cause quinolone resistance do not alter the cleavage activities of the enzymes. Therefore, 
these mutations cause resistance by altering drug-enzyme interactions. 
 Chapter IV describes the effects of quinolones and a quinazolinedione on the 
enzymatic activities of wild-type and quinolone-resistant mutant topoisomerase IV 
enzymes from B. anthracis. Portions of these findings have been published91,92 and 
demonstrate that quinolone resistance mutations decrease quinolone potency by reducing 
drug-enzyme interaction. In addition, these mutations also interfere with the ability of 
quinolones, but not quinazolinediones, to inhibit enzyme-mediated DNA religation and to 
form stable cleavage complexes. 
 Chapter V describes functional biochemical evidence supporting the water-metal 
ion bridge interaction between quinolones and bacterial type II topoisomerases that was 
identified in a crystal structure.43 A portion of these findings have been published91,92 and 
demonstrate that the water-metal ion bridge is the major point of interaction between the 
quinolones and topoisomerase IV. In addition, they show that the conserved serine and 
acidic residues act as the protein anchors of the bridge and explain how mutations at 
these residues cause quinolone resistance, namely by disrupting the water-metal ion 
bridge. Finally, these findings suggest that quinazolinediones interact with 
topoisomerases independently of a metal-ion bridge interaction and overcome quinolone 
resistance by establishing other contacts with the enzymes. 
 Chapter VI describes the characterization of wild-type and two quinolone-
resistant mutant topoisomerase IV enzymes from E. coli. Results indicate that the 
mutations cause quinolone resistance by decreasing drug efficacy and, to a lesser extent, 
drug potency. In addition, the ability of a quinolone, but not a quinazolinedione, to inhibit 
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enzyme-mediated DNA religation and form stable cleavage complexes is reduced. 
Moreover, it appears that quinolone interactions with E. coli topoisomerase IV are 
mediated through the water-metal ion bridge.  
 Chapter VII describes the evaluation of the structure-activity relationships of three 
series of quinolones, quinazolinediones, and non-amino-quinazolinediones that are based 
on ciprofloxacin, moxifloxacin, and an experimental quinazolinedione containing a C7 
3’-(aminomethyl)pyrrolindinyl group. The majority of this work has been published93 and 
demonstrates that, as a whole, quinazolinediones are poorer drugs than their quinolone 
counterparts because they are essentially quinolones that lack their most important 
interaction (i.e., the water-metal ion bridge) with the enzymes. Therefore, 
quinazoliendiones that overcome quinolone resistance caused by mutations in gyrase and 
topoisomerase IV do so by forming additional interactions with the enzymes through 
their C7 (and other) substituents. Furthermore, clinically relevant quinolones do not 
cross-react with the human type II topoisomerases because these enzymes cannot support 
the water-metal ion bridge interaction. For this reason, the C7 groups that facilitate 
interactions with the bacterial type II enzymes can also form interactions with the human 
enzymes, resulting in compounds with undesirable cross-reactivity. However, the C8 and 
N3 substituents modulate activity against human type II enzymes to a much greater 
extent than they do with the bacterial enzymes. As a result, three compounds have been 
identified that maintain high activity against quinolone-resistant mutant B. anthracis 
topoisomerase IV but do not show cross-reactivity with human topoisomerase IIα. 
 Chapter VIII describes the evaluation of the structure-activity relationships of a 
series of quinolones, quinazolinediones, and non-amino-quinazolinediones based on CP-
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115,955, an experimental quinolone with high activity against both human and bacterial 
type II topoisomerases. Results indicate that CP-115,955-based compounds have high 
activity against human topoisomerase IIα because the enzyme has a very specific 
interaction with the C7 4’-hydroxyphenyl moiety of the drug. The relative activities of 
the compounds in vitro are also reflected in the intracellular context. Thus, it may be 
possible to develop certain quinolones as anticancer chemotherapeutics. The C7 4’-
hydroxyphenyl group does not appear to facilitate strong interactions with B. anthracis 
topoisomerase IV, as these compounds (like those based on the clinically relevant 
quinolones ciprofloxacin and moxifloxacin) do not have high activity against quinolone-
resistant mutant topoisomerase IV enzymes. This observation demonstrates that there are 
differences between the human and bacterial enzymes that can be distinguished by the C7 
group and provides hope that a moiety can be identified that selectively targets the wild-
type and quinolone-resistant mutant bacterial enzymes. 
 Concluding remarks on the research presented in this dissertation are provided in 
Chapter IX. 
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CHAPTER II 
 
METHODS 
 
Materials 
 
Enzymes 
 B. anthracis topoisomerase IV enzymes were purified using the procedure of 
Dong et al.94 with modifications. Genes encoding wild-type B. anthracis GrlA and GrlB 
were individually PCR-amplified from B. anthracis Sterne 34F2 chromosomal DNA and 
cloned into the pET15b (Novagen) expression vector, which provided an N-terminus 
6×His tag. Mutant quinolone-resistant GrlAS81F, GrlAS81Y, GrlAE85K, GrlAE85A, 
GrlAS81F/E85K, GrlAS81F/E85A, and GrlAV96A were generated by QuikChange (Stratagene) 
site-directed mutagenesis of the wild-type expression vector. Recombinant subunits were 
individually expressed in an E. coli BL21(DE3) ΔslyD strain. Cells were lysed by 
resuspension in CelLytic B (Sigma) containing protease inhibitors (Roche Complete 
Protease Inhibitor Cocktail, EDTA-free) and one passage through a French press at 
20,000 psi. The cell lysate was centrifuged at 20,000 × g for 30 min at 4°C to remove 
debris. The cleared lysate was incubated with 2 mL Ni-NTA agarose beads (Qiagen) for 
1 h at 4°C with end-over-end rotation. Following batch binding, the beads were pelleted 
by centrifugation at 100 × g at 4°C and were then washed with a buffer containing 1 M 
NaCl, 60 mM imidazole, and 20 mM Tris-HCl (pH 7.9) for 30 min at 4°C with end-over-
end rotation. Next, the beads underwent a series of four 1-min washes with a buffer 
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containing 500 mM NaCl, 60 mM imidazole, and 20 mM Tris-HCl (pH 7.9). Finally, the 
beads were loaded into a column, and the proteins were eluted at 4°C with 12 mL of a 
buffer containing 500 mM NaCl, 1 M imidazole, and 20 mM Tris-HCl (pH 7.9). Twelve 
1-mL fractions were collected, and fractions 2-11 were combined, injected into a 20kDa 
MWCO Slide-a-Lyzer dialysis cassette (Thermo), and dialyzed against 200 mM NaCl 
and 50 mM Tris-HCl (pH 7.5) at 4°C for 4 hours. The proteins were then dialyzed 
overnight at 4°C into 200 mM NaCl, 50 mM Tris-HCl (pH 7.5), and 20% glycerol and 
were subsequently stored at -80°C. Protein concentrations were determined by A280 
measurements, and the quality and purity of the subunits was determined by Coomassie 
staining following separation on a 7.5% SDS-PAGE gel. In all assays, topoisomerase IV 
was used as a 1:1 mixture of GrlA:GrlB.  
 E. coli topoisomerase IV enzymes (wild-type ParC, wild-type ParE, ParCS80L, and 
ParCE84K) were expressed and purified as previously described.95,96 
 Human topoisomerase IIα (wild-type and mutant) was expressed in 
Saccharomyces cerevisiae as previously described.97 The wild-type enzyme was 
expressed from YEpWob6 and purified as previously described.98 A modified YEpWob6 
vector containing the wild-type human topoisomerase IIα gene and a 6×His tag at the C-
terminus99 was obtained from Dr. Joseph Deweese (Lipscomb University). Mutations in 
the His-tagged gene were generated by QuikChange Lightning (Agilent) site-directed 
mutagenesis using the primer pair 5’-GTCTTCTTATCATCATGGTGAGTCGTCACTA 
ATGGAGACCATTATCAATTTGGC and 5’-­‐GCCAAATTGATAATGGTCTCCATTA 
GTGACGACTCACCATGATGATAAGAAGAC (mutated positions are underlined). 
The mutated gene encoding the M762S and M766E mutations was sequenced for 
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accuracy using the primer 5’-­‐GGTTTGAAACCAGGTCAGAG. Yeast cells containing 
human topoisomerase IIαM762S/M766E were lysed in Y-PER Plus (Thermo) containing 1 
mM β-mercaptoethanol and protease inhibitors as described by the manufacturer. Unless 
otherwise noted, the following purification steps were carried out at 4°C. After addition 
of 500 mM NaCl, the lysate was centrifuged for 10 min at 19000 × g. The cleared lysate 
was subjected to batch binding to 2 mL Ni-NTA agarose beads (Qiagen) for 30 min. The 
beads were then washed for 30 min in wash buffer 1 [1 M NaCl, 30 mM imidazole, 20 
mM Tris-HCl (pH 7.9), 1 mM β-mercaptoethanol, and protease inhibitors] followed by 
four 1-min washes at RT in wash buffer 2 (wash buffer 1 containing 500 mM NaCl rather 
than 1 M NaCl). Mutant human topoisomerase IIα was eluted with 12 mL of elution 
buffer [500 mM NaCl, 1 M imidazole, 20 mM Tris-HCl (pH 7.9), 1 mM 
β-­‐mercaptoethanol, and protease inhibitors], collecting 1-mL fractions. Fractions 2-11 
were injected into a 20kDa MWCO Slide-a-­‐Lyzer dialysis cassette (Thermo) and 
dialyzed for 4 hours into dialysis buffer 1 [750 mM KCl, 50 mM Tris-HCl (pH 7.7), 100 
µM EDTA, and 500 µM DTT] and for 16 hours into dialysis buffer 2 (dialysis buffer 1 
containing 40% glycerol). The purified protein was stored at -80°C. Protein concentration 
was determined by Bradford analysis, and the quality and purity of the enzyme was 
determined by Coomassie staining following separation on a 7.5% SDS-PAGE gel. His-
tagged wild-type topoisomerase IIα was prepared parallel to the mutant enzyme and 
displayed activities that were nearly identical to enzymes prepared as described above by 
the protocol of Kingma et al.98 (Figure 9). 
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Figure 9. DNA cleavage activities of His-tagged (WT-His) and untagged (WT) wild-type 
human topoisomerase IIα. Cleavage levels were assessed in the absence of drugs with 5 
mM Ca2+, rather than Mg2+, as the divalent metal ion. Error bars represent the standard 
deviation of three independent experiments. 
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DNA Substrates 
 Negatively supercoiled pBR322 plasmid DNA was prepared from E. coli using a 
Plasmid Mega Kit (Qiagen) as described by the manufacturer. Kinetoplast DNA (kDNA) 
was isolated from Crithidia fasciculata as previously described.100 Relaxed pBR322 
plasmid DNA was generated by treatment with topoisomerase I for 30 min as previously 
described,101 followed by phenol-chloroform-isoamyl alcohol extraction, ethanol 
precipitation, and resuspension in 5 mM Tris-HCl (pH 8.5) and 500 µM EDTA. Linear 
radiolabeled pBR322 was prepared as follows. Plasmid pBR322 DNA was linearized by 
treatment with HindIII. Terminal 5’-phosphates were removed by treatment with calf 
intestinal alkaline phosphatase and replaced with [32P]phosphate using T4 polynucleotide 
kinase and [γ-32P]ATP. The DNA was treated with EcoRI, and the 4,332 bp singly-end-
labeled fragment was purified from the small EcoRI-HindIII fragment by passage 
through a CHROMA SPIN+TE-100 column (Clontech).  
 
Quinolones and Quinazolinediones 
 Ciprofloxacin was obtained from LKT Laboratories, stored at -20°C as a 40 mM 
stock solution in 0.1 N NaOH, and diluted five-fold with 10 mM Tris-HCl (pH 7.9) 
immediately prior to use. Moxifloxacin was obtained from LKT Laboratories, and 
levofloxacin, sparfloxacin, and norfloxacin were obtained from Sigma-Aldrich. All other 
quinolones and quinazolinediones were synthesized using established methods as 
previously described.102-107 A list of these compounds can be found in Table 1. 8-Methyl-
cipro, 8-methoxy-cipro, CP-115,955, 8-methyl-955, and 8-methoxy-955 were stored at    
-20°C as 40 mM stock solutions in 0.1 N NaOH and diluted five-fold with 10 mM 
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Table 1. Full chemical, library, and abbreviated names of compounds used in this work. 
   
Name Library name Chemical name 
Cipro-dione UIHS-IIa-249 3-amino-7-(1-piperazinyl)-1-cyclopropyl-6-fluoro-
2,4(1H,3H)-quinazolinedione 
8-Methyl-cipro UILI-2-89 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-(1-
piperazinyl)-4-oxo-3-quinolinecarboxylic acid 
8-Methyl-cipro-
dione 
UILI-2-87 3-amino-7-(1-piperazinyl)-1-cyclopropyl-6-fluoro-8-
methyl-2,4(1H,3H)-quinazolinedione 
8-Methyl-cipro-
NA-dione 
UILI-2-75 7-(1-piperazinyl)-1-cyclopropyl-6-fluoro-8-methyl-
2,4(1H,3H)-quinazolinedione 
8-Methoxy-cipro UIHS-IIa-101 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-(1-
piperazinyl)-4-oxo-3-quinolinecarboxylic acid 
8-Methoxy-cipro-
dione 
UIHS-IIa-253 3-amino-7-(1-piperazinyl)-1-cyclopropyl-6-fluoro-8-
methoxy-2,4(1H,3H)-quinazolinedione 
Moxi-dione UIHS-IIa-251 3-amino-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-
b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-
2,4(1H,3H)-quinazolinedione 
8-Methyl-moxi UIHS-IIa-45 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-
[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-
4-oxo-3-quinolinecarboxylic acid 
8-Methyl-moxi-
dione 
UILI-2-81 3-amino-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-
b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methyl-
2,4(1H,3H)-quinazolinedione 
8-Methyl-moxi-
NA-dione 
UILI-2-83 7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-
yl]-1-cyclopropyl-6-fluoro-8-methyl-2,4(1H,3H)-
quinazolinedione 
8-H-moxi UIHS-IIa-239 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-
octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-
quinolinecarboxylic acid 
8-H-moxi-dione UIHS-IIa-247 3-amino-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-
b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-2,4(1H,3H)-
quinazolinedione 
8-Methyl-3'-
(AM)P-FQ 
UIHS-I-303 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-[(3S)-
3-(aminomethyl)-1-pyrrolidinyl]-4-oxo-3-
quinolinecarboxylic acid 
8-Methyl-3'-
(AM)P-dione 
UIJR-1-048 3-amino-7-[(3S)-3-(aminomethyl)-1-pyrrolidinyl]-1-
cyclopropyl-6-fluoro-8-methyl-2,4(1H,3H)-
quinazolinedione 
8-Methyl-3'-
(AM)P-NA-dione 
UILI-2-97 7-[(3S)-3-(aminomethyl)-1-pyrrolidinyl]-1-
cyclopropyl-6-fluoro-8-methyl-2,4(1H,3H)-
quinazolinedione 
8-Methoxy-3'-
(AM)P-FQ 
UING-5-249 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-
[(3S)-3-(aminomethyl)-1-pyrrolidinyl]-4-oxo-3-
quinolinecarboxylic acid 
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Table 1. (Continued) 
   
Name Library name Chemical name 
8-Methoxy-3'-
(AM)P-dione 
UING-5-207 3-amino-7-[(3S)-3-(aminomethyl)-1-pyrrolidinyl]-1-
cyclopropyl-6-fluoro-8-methoxy-2,4(1H,3H)-
quinazolinedione 
8-H-3'-(AM)P-FQ UIHS-IIIa-35 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-[(3S)-3-
(aminomethyl)-1-pyrrolidinyl]-4-oxo-3-
quinolinecarboxylic acid 
8-H-3'-(AM)P-
dione 
UIHS-IIa-245 3-amino-7-[(3S)-3-(aminomethyl)-1-pyrrolidinyl]-1-
cyclopropyl-6-fluoro-2,4(1H,3H)-quinazolinedione 
CP-115,953 CP-115,953 1-Cyclopropyl-6,8-difluoro-1,4-dihydro-7-(4-
hydroxyphenyl)-4-oxo-3-quinolinecarboxylic acid 
CP-115,955 CP-115,955 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(4-
hydroxyphenyl)-4-oxo-3-quinolinecarboxylic acid 
955-dione UILI-2-61 3-amino-7-(4-hydroxyphenyl)-1-cyclopropyl-6-fluoro-
2,4(1H,3H)-quinazolinedione 
955-NA-dione UILI-2-63 7-(4-hydroxyphenyl)-1-cyclopropyl-6-fluoro-
2,4(1H,3H)-quinazolinedione 
8-Methyl-955 UIHS-IIIa-23 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-(4-
hydroxyphenyl)-4-oxo-3-quinolinecarboxylic acid 
8-Methyl-955-
dione 
UILI-2-297 3-amino-7-(4-hydroxyphenyl)-1-cyclopropyl-6-fluoro-
8-methyl-2,4(1H,3H)-quinazolinedione 
8-Methyl-955-NA-
dione 
UILI-2-257 7-(4-hydroxyphenyl)-1-cyclopropyl-6-fluoro-8-methyl-
2,4(1H,3H)-quinazolinedione 
8-Methoxy-955 UIHS-IIIa-27 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-
hydroxyphenyl)-4-oxo-3-quinolinecarboxylic acid 
8-Methoxy-955-
dione 
UILI-3-11 3-amino-7-(4-hydroxyphenyl)-1-cyclopropyl-6-fluoro-
8-methoxy-2,4(1H,3H)-quinazolinedione 
8-Methoxy-955-
NA-dione 
UILI-2-289 7-(4-hydroxyphenyl)-1-cyclopropyl-6-fluoro-8-
methoxy-2,4(1H,3H)-quinazolinedione 
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Tris-HCl (pH 7.9) immediately prior to use. All other quinolones and quinazolinediones 
were stored at 4°C as 20 mM stock solutions in DMSO. 
 
Other Materials 
 [γ-32P]ATP (~6000 Ci/mmol) and [γ-32P]ATP (~3000 Ci/mmol) were obtained 
from PerkinElmer. Histone H1 was obtained from Boehringer Mannheim. Plastic-backed 
20×20 cm polyethyleneimine-impregnated cellulose F thin layer chromatography (TLC) 
plates were obtained from EMD Chemicals. Rabbit anti-human topoisomerase IIα 
antibody was obtained from Abcam. Donkey anti-rabbit antibody (IRDye 680 LT) for use 
with the Li-Cor Odyssey system was obtained from Li-Cor. Nitrocellulose membrane 
was acquired from PerkinElmer. 
 
Bacillus anthracis Topoisomerase IV Assays 
 
DNA Relaxation 
 DNA relaxation assays were based on the protocol of Fortune and Osheroff.108 
Reaction mixtures (20 µL) contained 18.75 nM wild-type or mutant topoisomerase IV 
and 5 nM negatively supercoiled pBR322 in relaxation buffer [40 mM HEPES (pH 7.6), 
100 mM potassium glutamate, 10 mM Mg(OAc)2, 50 mM NaCl, and 1 mM ATP] and 
were incubated at 37°C. Relaxation was stopped at times ranging from 0-30 min by the 
addition of 3 µL of stop solution [0.77% SDS and 77.5 mM EDTA]. Samples were mixed 
with 2 µL of agarose gel loading buffer [60% sucrose, 10 mM Tris-HCl (pH 7.9), 0.5% 
bromophenol blue, and 0.5% xylene cyanol FF], heated at 45°C for 5 min, and subjected 
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to electrophoresis in 1% agarose gels in 100 mM Tris-borate (pH 8.3) and 2 mM EDTA. 
Gels were stained with 0.75 µg/mL ethidium bromide for 30 min. DNA bands were 
visualized with medium-range ultraviolet light and quantified using an AlphaInnotech 
digital imaging system. The percent relaxed DNA was determined by the loss of 
supercoiled DNA substrate. 
 
Kinetoplast DNA Decatenation 
 Decatenation assays were carried out by the procedure of Anderson et al.109 
Reaction mixtures (20 µL) contained 18.75 nM wild-type or mutant topoisomerase IV 
and 0.3 µg kinetoplast DNA (kDNA) in relaxation buffer and were incubated at 37°C. 
Decatenation was stopped at times ranging from 0-30 min by the addition of 3 µL of stop 
solution. Samples were mixed with 2 µL of agarose gel loading buffer, heated at 45°C for 
5 min, and subjected to electrophoresis in 1% agarose gels in 100 mM Tris-borate (pH 
8.3) and 2 mM EDTA containing 0.5 µg/mL ethidium bromide. DNA bands were 
visualized and quantified as described above. The percent decatenated DNA was 
determined by the appearance of monomeric circular DNA molecules. 
 
Plasmid DNA Catenation 
 Catenation assays were based on the protocol of Fortune and Osheroff.110 
Reactions (20 µL) contained 50 nM wild-type or mutant topoisomerase IV and 5 nM 
relaxed pBR322 in relaxation buffer containing 25 mM NaCl (rather than 50 mM) and 
supplemented with 5 µg/mL histone H1 and were incubated at 37°C. Catenation was 
stopped at times ranging from 0-30 min by the addition of 2 µL of 250 mM EDTA (pH 
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8.0) followed by 2 µL of 1.25% SDS. Samples were mixed with 2 µL of agarose gel 
loading buffer, heated at 45°C for 5 min, and subjected to electrophoresis in 1% agarose 
gels in 100 mM Tris-borate (pH 8.3) and 2 mM EDTA containing 0.5 µg/mL ethidium 
bromide. DNA bands were visualized and quantified as described above. The percent 
catenated DNA was determined by the loss of relaxed monomers or the appearance of 
catenated products retained in the wells (both yielded similar results).  
 Non-turnover catenation reactions contained 200 nM wild-type or mutant 
topoisomerase IV and substituted 1 mM APP(NH)P for ATP. Prior to electrophoresis, 
reactions were treated with proteinase K (2 µL of a 0.8 mg/mL solution) at 45°C for 45 
min to digest the enzyme. 
 
ATP Hydrolysis 
 ATP hydrolysis assays were carried out as described by Kingma et al.111 
Reactions (20 µL) contained 100 nM wild-type or mutant topoisomerase IV and 85 nM 
negatively supercoiled pBR322 in relaxation buffer supplemented with 150 nM [γ-
32P]ATP and were incubated at 37°C. Reactions carried out in the absence of DNA 
contained 500 nM wild-type or mutant topoisomerase IV. Reactions were terminated at 
0-14 min by spotting 2 µL on a TLC plate. Standards were spotted at the top of each plate 
and consisted of 1, 2, and 3 µL of a 50-fold diluted reaction. Plates were developed in 
400 mM NH4HCO3. Following air-drying, plates were covered in plastic wrap and 
exposed for 30 min to a K screen. The K screen was visualized and hydrolyzed phosphate 
was quantified using a Bio-Rad Molecular Imager FX. 
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Plasmid DNA Cleavage   
 DNA cleavage reactions were carried out using the procedure of Fortune and 
Osheroff.108 Reactions contained 75 nM wild-type or mutant topoisomerase IV and 10 
nM negatively supercoiled pBR322 in a total of 20 µL of cleavage buffer [40 mM Tris-
HCl (pH 7.9), 10 mM MgCl2, 50 mM NaCl, and 2.5% (v/v) glycerol]. Reaction mixtures 
were incubated at 37°C for 10 min, and enzyme-DNA cleavage complexes were trapped 
by the addition of 2 µL of 5% SDS followed by 2 µL of 250 mM EDTA (pH 8.0). 
Proteinase K (2 µL of a 0.8 mg/mL solution) was added, and samples were incubated at 
45°C for 45 min to digest the enzyme. Samples were mixed with 2 µL of agarose gel 
loading buffer, heated at 45°C for 5 min, and subjected to electrophoresis in 1% agarose 
gels in 40 mM Tris-acetate (pH 8.3) and 2 mM EDTA containing 0.5 µg/mL ethidium 
bromide. DNA bands were visualized and quantified as described above. DNA cleavage 
was monitored by the conversion of supercoiled plasmid to linear molecules.  
 Assays that monitored the DNA cleavage activities of wild-type and mutant 
topoisomerase IV in the absence of drugs substituted 10 mM CaCl2 for 10 mM MgCl2 in 
the cleavage buffer. Ca2+ supports higher levels of topoisomerase IV-mediated DNA 
cleavage in the absence of drugs, thereby facilitating quantification of basal enzyme 
activity. It should be noted that Ca2+ does not significantly alter the reversibility or the 
stability of cleavage complexes as compared to Mg2+.  
 Assays that assessed the DNA cleavage activities of the wild-type and mutant 
enzymes in the presence of drugs contained 0-500 µM of the indicated compound. For 
assays that monitored competition between two drugs, the compounds were added 
simultaneously to reaction mixtures, and the final concentration of the compounds is 
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indicated. In these competition assays, the level of cleavage seen with the corresponding 
concentration of the competing drug in the absence of the drug held at a constant 
concentration across the assay was used as a baseline and was subtracted from the 
cleavage level seen in the presence of both compounds. In some reactions, the 
concentration dependence of MgCl2 was examined or the divalent metal ion was replaced 
with CaCl2, ZnCl2, CdCl2, MnCl2, or NiCl2. The final concentration of these alternative 
metal ions in the reactions is indicated in the relevant figures.  
 
DNA Cleavage Site Utilization 
 DNA cleavage sites were mapped using a modification112 of the procedure of 
O’Reilly and Kreuzer.113 Reaction mixtures contained 50 nM wild-type or mutant 
topoisomerase IV and 1 nM radiolabeled pBR322 DNA substrate in 50 µL of DNA 
cleavage buffer in the absence or presence of compounds. Reaction mixtures were 
incubated at 37°C for 10 min, and enzyme-DNA cleavage complexes were trapped by the 
addition of 5 µL of 5% SDS followed by 3 µL of 250 mM EDTA (pH 8.0). Proteinase K 
(5 µL of a 0.8 mg/mL solution) was added, and samples were incubated at 45°C for 45 
min to digest the enzyme. DNA products were precipitated with ethanol and resuspended 
in 5 µL of polyacrylamide gel loading buffer [10% agarose gel loading buffer, 80% 
formamide, 100 mM Tris-borate (pH 8.3), and 2 mM EDTA]. Samples were subjected to 
electrophoresis in denaturing 6% polyacrylamide sequencing gels. Gels were dried in 
vacuo, and DNA cleavage products were visualized with a Bio-Rad Molecular Imager 
FX. 
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DNA Religation 
 DNA religation assays were carried out using the procedure of Robinson and 
Osheroff.114 Reactions (20 µL) contained 75 nM wild-type or mutant topoisomerase IV 
and 10 nM negatively supercoiled pBR322 in cleavage buffer containing 5 mM MgCl2 
(rather than 10 mM). Reactions carried out in the presence of drug contained the 
indicated compound at the concentration listed. Reactions carried out in the absence of 
drug substituted 1 mM CaCl2 for 5 mM MgCl2. Initial DNA cleavage/religation equilibria 
were established at 37°C for 10 min. Religation was initiated by rapidly shifting the 
reaction temperature from 37 to 75°C. The shift to high temperature allows enzyme-
mediated religation but prevents new rounds of DNA cleavage from occurring. Thus, it 
results in a unidirectional sealing of the cleaved DNA. Reactions were stopped at times 
ranging from 0-135 s by the addition of 2 µL of 5% SDS followed by 2 µL of 250 mM 
EDTA (pH 8.0). Samples were digested with proteinase K and processed as described 
above for plasmid cleavage assays. Levels of DNA cleavage were set to 100% at time 
zero, and religation was determined by the loss of linear cleavage product over time. 
 
Persistence of Topoisomerase IV-DNA Cleavage Complexes 
 The persistence of topoisomerase IV-DNA cleavage complexes established in the 
presence of drugs was determined using the procedure of Gentry et al.115 Initial reaction 
mixtures contained 375 nM wild-type or mutant topoisomerase IV, 50 nM DNA, and 20 
µM (for the wild-type enzyme) or 200 µM (for the mutant enzymes) ciprofloxacin or 20 
µM 8-methyl-3’-(AM)P-dione in a total of 20 µL of DNA cleavage buffer. Reactions 
were incubated at 37°C for 10 min and then diluted 20-fold with DNA cleavage buffer 
38 
 
warmed to 37°C. Samples (20 µL) were removed at times ranging from 0-300 min, and 
DNA cleavage was stopped with 2 µL of 5% SDS followed by 2 µL of 250 mM EDTA 
(pH 8.0). Samples were digested with proteinase K and processed as described above for 
plasmid cleavage assays. Levels of DNA cleavage were set to 100% at time zero, and the 
persistence of cleavage complexes was determined by the decay of the linear reaction 
product over time. 
 
Escherichia coli Topoisomerase IV Assays 
 Assays utilizing E. coli topoisomerase IV were carried out as described above for 
B. anthracis topoisomerase IV with the following modifications. All assays utilizing 
wild-type or ParCS80L topoisomerase IV contained 10 nM enzyme. All assays utilizing 
ParCE84K topoisomerase IV contained 25 nM enzyme. Cleavage buffer contained 2.5 mM 
MgCl2 (rather than 10 mM). In some reactions, 2.5 mM CaCl2 was substituted for the 
MgCl2. Religation assays carried out in the absence of drugs did not substitute CaCl2 for 
MgCl2. The persistence of cleavage complexes was measured from 0-30 min, and initial 
reactions contained 50 nM wild-type or ParCS80L topoisomerase IV. 
 
Human Topoisomerase IIα Assays 
 
Plasmid DNA Cleavage 
 DNA cleavage reactions were carried out using the procedure of Fortune and 
Osheroff.108 Reactions that tested the effects of drugs on wild-type topoisomerase IIα 
contained 110 nM enzyme and 10 nM negatively supercoiled pBR322 in a total of 20 µL 
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of 10 mM Tris-HCl (pH 7.9), 5 mM MgCl2, 100 mM KCl, 100 µM EDTA, 25 µM DTT, 
and 2.5% (v/v) glycerol. Reactions that compared the effects of drugs on wild-type and 
mutant M762S/M766E topoisomerase IIα contained 110 nM enzyme and 10 nM 
negatively supercoiled pBR322 plasmid DNA in a total of 20 µL of 10 mM Tris-HCl (pH 
7.7), 5 mM MgCl2, 140 mM KCl, 20 µM EDTA, 90 µM DTT, 7.5% (v/v) glycerol, and 1 
mM ATP. The slight differences in buffer components (as compared to the above) reflect 
the fact that the mutant enzyme was more dilute than the wild-type enzyme preparation. 
These buffer differences had no effect on topoisomerase IIα activity. Reaction mixtures 
were incubated at 37°C for 10 min and processed as described above for topoisomerase 
IV plasmid DNA cleavage. 
 Assays that monitored competition between two drugs were carried out as 
described above for topoisomerase IV.  
 
Persistence of Topoisomerase IIα-DNA Cleavage Complexes 
 Persistence of topoisomerase IIα cleavage complexes was assessed as described 
above for topoisomerase IV. Initial reactions contained 550 nM enzyme and 20 µM CP-
115,955 or 200 µM 955-dione. Following a 25-fold dilution, the persistence of cleavage 
complexes was measured from 0-1 min. 
 
Intracellular Cleavage Complex Formation 
 Levels of topoisomerase IIα cleavage complexes formed in human CEM cells 
upon drug treatment were determined using the rapid approach to DNA adduct recovery 
(RADAR) assay116 with modifications. Cells were grown in RPMI 1640 + L-glutamine 
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culture medium supplemented with 10% bovine growth serum. 600,000 cells were seeded 
at a density of 150,000 cells/mL in 6-well cell culture plates. Following a 24 h incubation 
at 37°C, cells were treated with drugs for 1 h at 37°C. Cells were harvested by 
centrifugation (500 × g for 5 min at RT) and lysed with 4 M guanidine thiocyanate, 20 
mM Tris-HCl, 20 mM EDTA, 2% Triton X-100, 1% Sarkosyl, 1% DTT, and 100 mM 
NaOAc, at pH 6.5 (personal communication with Kostantin Kiianitsa, University of 
Washington). Lysates were sheared with four passages through a 21-gauge needle and 
ethanol precipitated as described116 for at least 20 min. Precipitated DNA was pelleted by 
centrifugation at 18,000 × g for 20 min at 4°C. Pellets were washed and resuspended in 8 
mM NaOH as described.116 DNA solutions were subjected to at least eight shearing 
passes through a 21-gauge needle. Levels of DNA-topoisomerase IIα cleavage complexes 
were determined by immunoblotting for topoisomerase IIα on 0.5 µg genomic DNA. 
Immunoblots were visualized and quantified using the Li-Cor Odyssey system. 
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CHAPTER III 
 
ENZYMATIC ACTIVITIES OF WILD-TYPE AND MUTANT QUINOLONE- 
RESISTANT TOPOISOMERASE IV FROM BACILLUS ANTHRACIS 
 
Introduction 
 Quinolones kill bacterial cells by increasing levels of double-stranded DNA 
breaks generated by the bacterial type II topoisomerases gyrase and topoisomerase 
IV.4,18,35-39 However, the molecular mechanism by which quinolones interact with and 
stabilize cleavage complexes is not well understood. A recent structural study has 
suggested that quinolones interact with the bacterial type II enzymes through a water-
metal ion interaction that “bridges” the drug to the protein through a serine and an acidic 
residue.43 These two residues are also the most commonly mutated amino acids in 
quinolone-resistant bacterial strains.18,36,37,39,49,77-83 
 To further our understanding of quinolone-topoisomerase interactions and how 
specific mutations in the enzyme result in quinolone resistance, it is necessary to first 
characterize the enzymatic activities of wild-type and mutant quinolone-resistant 
topoisomerase IV in the absence of drugs. Topoisomerase mutations could cause 
quinolone resistance by altering drug-enzyme interactions, which could decrease drug 
efficacy and/or drug potency. Alternatively, mutations could affect the enzyme directly 
by decreasing its concentration in the cell, its stability, and/or its level of activity. While 
mutations that affect drug-enzyme interactions could be overcome by designing new 
drugs, resistance that is caused by the latter effects on the enzyme cannot. 
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 Topoisomerase IV from B. anthracis was used as the model to characterize the 
basal (i.e. in the absence of drugs) activity levels of wild-type and quinolone-resistant 
mutant enzymes. The mutant topoisomerases that were evaluated include GrlAS81F, 
GrlAS81Y, GrlAE85K, and GrlAV96A. The Ser81 and Glu85 mutant enzymes contain 
alterations at the amino acid residues suggested to participate in the water-metal ion 
bridge interaction (Figure 7) identified in the crystallographic study43 discussed earlier. 
These two residues are highly conserved across bacterial species and are the residues 
most commonly mutated in quinolone-resistant strains.18,36,37,39,49,77-83 The Val96 mutant 
enzyme contains an alteration at an amino acid located on the same α helix (specifically, 
helix α4) as Ser81 and Glu85, but it is not in close enough proximity to the drug binding 
pocket to participate in the water-metal ion bridge interaction that is proposed to facilitate 
quinolone-topoisomerase binding. Val96 mutations are observed much less frequently 
than Ser81 or Glu85 mutations in drug-resistant clinical and laboratory 
strains.18,36,37,39,49,77-85 Characterization of the enzymatic activities of these enzymes will 
provide information regarding the nature of the most commonly observed quinolone 
resistance mutations. 
 
Results and Discussion 
 
Characterization of the Catalytic Activities of Wild-type and Quinolone-Resistant Mutant 
Topoisomerase IV 
 The cellular functions of topoisomerase IV include the removal of DNA 
supercoils and the unlinking of daughter chromosomes. These catalytic activities were 
assessed in vitro by evaluating the ability of the enzyme to relax negatively supercoiled 
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plasmid DNA and decatenate the mini- and maxi-circles that make up kinetoplast DNA 
(kDNA).  
 GrlAS81F and GrlAS81Y, as well as GrlAV96A, topoisomerase IV relax DNA at 
approximately the same rate as the wild-type enzyme (Figure 10). The Ser81 mutants can 
also decatenate kDNA at a rate that is identical to that of wild-type topoisomerase IV 
(Figure 10). Therefore, these mutations of Ser81 and Val96 do not affect the catalytic 
activity of the enzyme. In contrast, GrlAE85K displays a significantly decreased rate of 
DNA relaxation as compared to the wild-type enzyme. A similar decrease in catalytic 
activity has been reported for the equivalent GluLys mutation in E. coli topoisomerase 
IV.117 This finding raised the possibility that GrlAE85K topoisomerase IV displays 
quinolone resistance because it has low overall activity. Therefore, the Glu85 mutant 
enzyme was further evaluated to shed light on the underlying basis of its decreased 
catalytic rate.  
 First, the ability of GrlAE85K topoisomerase IV to hydrolyze ATP was 
characterized. In the absence of DNA, the basal rates of ATP hydrolysis catalyzed by the 
mutant and wild-type enzymes were indistinguishable (Figure 11). In the presence of 
DNA, the hydrolysis rate of the mutant enzyme was slightly slower than that of wild-type 
(Figure 11), but was not sufficiently impaired to account for the large difference in the 
rate of DNA relaxation discussed above. Thus, the impaired overall activity of GrlAE85K 
does not appear to reflect an altered interaction with the ATP cofactor. 
 Second, the ability of GrlAE85K topoisomerase IV to carry out catalytic and non-
turnover DNA catenation was assessed. As expected based on the DNA relaxation 
results, the mutant enzyme catalyzed DNA catenation (in the presence of ATP) at a rate 
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Figure 10. Catalytic activities of wild-type and quinolone-resistant mutant B. anthracis 
topoisomerase IV enzymes. The ability of wild-type, GrlAS81F, GrlAS81Y, GrlAE85K, and 
GrlAV96A topoisomerase IV to relax negatively supercoiled pBR322 plasmid DNA is 
shown on the left. The ability of wild-type, GrlAS81F, and GrlAS81Y topoisomerase IV to 
decatenate kinetoplast DNA is shown on the right. Error bars represent the standard 
deviation of at least three independent experiments. 
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Figure 11. ATP hydrolysis catalyzed by wild-type and GrlAE85K topoisomerase IV from 
B. anthracis. The abilities of the enzymes to hydrolyze ATP in the absence (left) or 
presence (right) of negatively supercoiled pBR322 plasmid DNA are shown. Error bars 
represent the standard deviation of at least three independent experiments. 
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 that was much slower than that of the wild-type enzyme (Figure 12). Non-turnover 
reactions utilized APP(NH)P, a non-hydrolyzable ATP analog that allows each 
topoisomerase IV enzyme to carry out only one DNA strand passage event. In contrast to 
wild-type topoisomerase IV, GrlAE85K displayed very little ability to catalyze DNA strand 
passage under non-turnover conditions (Figure 12). Therefore, the decreased catalytic 
rate of the mutant enzyme likely occurs at a step that precedes enzyme turnover. 
 
Characterization of the DNA Cleavage Activities of Wild-type and Quinolone-Resistant 
Mutant Topoisomerase IV 
 Quinolones kill bacterial cells primarily by increasing levels of DNA cleavage 
mediated by gyrase and topoisomerase IV.4,18,35-39 Because the cleavage step occurs early 
in the catalytic cycle of the enzymes and does not depend on ATP,17-23 mutations can 
have a different effect on enzyme-mediated DNA cleavage than they do on catalytic 
processes, such as relaxation or decatenation. Therefore, even if a mutant enzyme has 
altered catalytic activity, it may retain a wild-type level of cleavage activity, which is the 
function that is important for quinolone action. Thus, the ability of wild-type, GrlAS81F, 
GrlAS81Y, GrlAE85K, and GrlAV96A topoisomerase IV to cleave DNA was examined. 
 Although the DNA cleavage reaction is ATP independent, a divalent metal ion is 
required for the enzyme to cut the double-helix.17-26 The cleavage reaction of B. anthracis 
topoisomerase IV could be supported by Mg2+, Ca2+, and Mn2+ (Figure 13, inset). As 
observed for other prokaryotic and eukaryotic type II enzymes,26,118-120 high levels of 
DNA scission were seen in reactions that contained Ca2+. A number of other divalent 
metal ions (Ba2+, Sr2+, Cd2+, Co2+, Ni2+, Zn2+, and Pb2+) and even a few trivalent metal 
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Figure 12. Catalytic and non-turnover catenation mediated by wild-type and GrlAE85K 
topoisomerase IV from B. anthracis. The ability of the enzymes to catalyze catenation of 
relaxed pBR322 plasmid DNA is shown on the left. The ability of the enzymes to carry 
out strand passage is shown on the right. These “non-turnover” assays utilized the non-
hydrolyzable ATP analog APP(NH)P and relaxed pBR322 plasmid DNA to observe a 
single DNA strand passage (i.e., catenation) event. Error bars represent the standard 
deviation of at least three independent experiments. 
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Figure 13. DNA cleavage activities of wild-type, GrlAS81F, GrlAS81Y, GrlAE85K, and 
GrlAV96A topoisomerase IV from B. anthracis. The ability of the enzymes to cleave 
negatively supercoiled pBR322 plasmid DNA in the absence of drugs is shown. Assays 
were carried out in the presence of 10 mM CaCl2. Error bars represent the standard 
deviation of at least three independent experiments. The inset shows an agarose gel of a 
typical DNA cleavage assay mediated by wild-type topoisomerase IV in the absence of 
divalent metal ion (None) or in the presence of 10 mM Mg2+, Ca2+, or Mn2+. 
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ions (Al3+, Eu3+, and Tb3+) could also support varying levels of enzyme-mediated DNA 
cleavage (not shown). 
 Because Ca2+ supported much higher (and, thus, more readily quantifiable) levels 
of DNA cleavage than did Mg2+, it was used in assays that assessed the ability of the 
enzymes to cleave DNA in the absence of drugs. As seen with DNA relaxation and 
decatenation, GrlAS81F, GrlAS81Y, and GrlAV96A topoisomerase IV retained wild-type 
levels of activity (Figure 13). In contrast to results seen with the catalytic assays, the 
GrlAE85K mutant enzyme also cleaved plasmid DNA with an activity that was similar to 
that of wild-type topoisomerase IV (Figure 13). This latter finding suggests that the steps 
of the catalytic cycle of GrlAE85K that precede the strand passage event [enzyme-DNA 
binding, DNA bending, and DNA cleavage17-19,22,27,28,34,121] are relatively unaffected in 
the mutant enzyme and implies that the Glu85Lys mutation decreases the overall 
catalytic activity of B. anthracis topoisomerase IV by impairing the DNA strand passage 
event. Furthermore, it provides strong evidence that quinolone resistance in GrlAE85K, as 
well as GrlAS81F, GrlAS81Y, and GrlAV96A, topoisomerase IV is not caused by a general 
loss of activity and likely reflects altered drug-enzyme interactions.  
 
Summary of Conclusions 
 Bacillus anthracis GrlAS81F, GrlAS81Y, and GrlAV96A mutant topoisomerase IV 
retain wild-type levels of both catalytic and cleavage activities. However, the GrlAE85K 
enzyme displays a significantly impaired catalytic ability, while at the same time 
retaining wild-type levels of cleavage activity. In addition, this enzyme hydrolyzes ATP 
at a similar rate to wild-type topoisomerase IV, both in the absence and presence of 
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DNA. Finally, in non-turnover catenation reactions, the GrlAE85K mutant shows very little 
ability to link plasmid DNA molecules. Taken together, these results indicate that the 
GluLys mutation likely decreases the catalytic activity of the enzyme by impairing 
strand passage. Moreover, all of these mutations appear to cause quinolone resistance by 
altering drug-enzyme interactions. 
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CHAPTER IV 
 
EFFECTS OF QUINOLONES AND A QUINAZOLINEDIONE ON WILD-TYPE 
AND MUTANT QUINOLONE-RESISTANT TOPOISOMERASE IV 
FROM BACILLUS ANTHRACIS 
 
Introduction 
 The most clinically significant form of quinolone resistance is caused by point 
mutations in the topoisomerase enzymes targeted by these drugs.18,36,37,39,49,77 A specific 
serine and acidic residue, located four positions downstream of the serine, are the 
residues that are most frequently mutated in resistant clinical and laboratory 
strains.18,36,37,39,49,77-83 (In B. anthracis topoisomerase IV, these residues are Ser81 and 
Glu85.) Both of these amino acids are highly conserved across bacterial species. 
Although the involvement of these amino acid residues in quinolone resistance has been 
known for well over a decade, the mechanistic basis by which their alteration leads to 
resistance remains an enigma.  
 A recent crystallographic study suggested that quinolones bind to type II 
topoisomerases through a metal ion chelated by the C3/C4 keto acid moiety of the drug.43 
In this structure, the metal ion was stabilized by four water molecules, two of which were 
coordinated by the serine and acidic residues. The authors suggested that this interaction 
was important for quinolone-enzyme binding and that mutation of either the serine or 
acidic residue could cause quinolone resistance by disrupting this interaction.43 As a first 
step toward testing this idea and shedding light on the molecular mechanism of quinolone 
action and resistance, the effects of quinolones on wild-type, GrlAS81F, GrlAS81Y, 
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GrlAV96A, and GrlAE85K topoisomerase IV were evaluated. For comparison, the activity of 
a quinazolinedione against these enzymes was also examined. Quinazolinediones have 
been to shown to overcome quinolone resistance caused by topoisomerase IV and gyrase 
mutations.91-93,105,107,122-124 These compounds are structurally similar to quinolones, but 
they lack the C3/C4 keto acid necessary to chelate metal ions. Thus, they presumably 
maintain activity against mutant enzymes by functioning independently of bridging 
water-metal ion interactions. 
 
Results and Discussion 
 
Effects of Quinolones and a Quinazolinedione on DNA Cleavage Mediated by Wild-Type 
and Mutant Quinolone-Resistant Topoisomerase IV 
 Quinolones kill bacteria by increasing the number of topoisomerase-DNA 
cleavage complexes in the cell. These normally transient breaks are converted to 
permanent strand breaks that can overwhelm DNA repair processes and ultimately lead to 
cell death.4,18,35-39 To begin exploring how quinolones interact with topoisomerases, a 
number of clinically relevant quinolones39 – ciprofloxacin, levofloxacin, moxifloxacin, 
norfloxacin, and sparfloxacin – were tested for their ability to enhance DNA cleavage 
mediated by wild-type topoisomerase IV (Figure 14). Ciprofloxacin was the most potent 
quinolone and, together with levofloxacin, was the most efficacious. Because these two 
drugs are also the most frequently prescribed members of the class, they were then tested 
with GrlAS81F and GrlAS81Y topoisomerase IV.  
 As predicted from quinolone resistance studies with B. anthracis cultures77,84,85 
and previous studies with gyrase and topoisomerase IV from other bacterial species that 
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Figure 14. Effects of quinolones and 8-methyl-3’-(AM)P-dione on the DNA cleavage 
activities of wild-type, GrlAS81F, GrlAS81Y, GrlAE85K, and GrlAV96A topoisomerase IV 
from B. anthracis. Results with ciprofloxacin and 8-methyl-3’-(AM)P-dione are shown 
for all enzymes. Results with levofloxacin are shown for wild-type, GrlAS81F, and 
GrlAS81Y. Results with norfloxacin, moxifloxacin, and sparfloxacin are shown for wild-
type. The structures of ciprofloxacin and 8-methyl-3’-(AM)P-dione are also shown. Error 
bars represent the standard deviation of at least three independent experiments. 
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carry mutations at this serine residue,78,119,123-125 ciprofloxacin and levofloxacin displayed 
decreased activity against GrlAS81F and GrlAS81Y topoisomerase IV (Figure 14). The 
quinolone concentration required to triple levels of enzyme-mediated DNA cleavage 
(CC3) rose ~27- to 42-fold with GrlAS81F topoisomerase IV (as compared to the wild-type 
enzyme) and ~10- to 17-fold with GrlAS81Y topoisomerase IV (Table 2).  
 Because ciprofloxacin displayed slightly higher activity than levofloxacin against 
both serine mutants, it was also tested with GrlAE85K and GrlAV96A topoisomerase IV. 
The GrlAE85K mutant enzyme displayed significant resistance to ciprofloxacin (Figure 
14). The CC3 (~43 µM) rose ~80-fold as compared to wild-type (~0.5 µM) (Table 2). The 
GrlAV96A mutant enzyme showed a much lower level of resistance to ciprofloxacin than 
did the other mutant enzymes (Figure 14). The CC3 was ~2.5-fold higher against this 
mutant enzyme than against the wild-type enzyme (Table 2). Because the V96A mutation 
is located away from the proposed water-metal ion interaction discussed above, it is not 
surprising that this mutant enzyme retains more sensitivity to the quinolone than do the 
topoisomerases possessing mutations in the amino acids suggested to facilitate quinolone-
enzyme interactions through this mechanism. 
 To determine the effects of the mutations on the efficacy of quinolone action, 
maximal levels of DNA cleavage were obtained by extending the drug concentration 
range (Figure 15). Levels of DNA cleavage observed with the mutant enzymes at high 
concentrations of ciprofloxacin approached those seen at lower drug concentrations with 
wild-type topoisomerase IV. Similar results were observed for levofloxacin and 
moxifloxacin (Figure 15). Drug efficacy (i.e., the maximal level of DNA cleavage) 
ranged from 0.61 to 1.2 for the various mutant topoisomerase IV enzymes as compared to 
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Figure 15. Maximal levels of quinolone-induced DNA cleavage mediated by wild-type 
and quinolone-resistant mutant B. anthracis topoisomerase IV enzymes. A titration is 
shown for ciprofloxacin with wild-type, GrlAS81F, GrlAS81Y, GrlAE85K, and GrlAV96A 
(left). Maximal levels of DNA cleavage induced by wild-type, GrlAS81F, GrlAS81Y, and 
GrlAE85K in the presence of levofloxacin and moxifloxacin are shown at the right. 
Levofloxacin and moxifloxacin concentrations with the wild-type enzyme were 20 µM 
and with the mutant enzymes were 500 µM. Error bars represent the standard deviation of 
at least three independent experiments.  
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the wild-type enzyme (Table 2). These results indicate that quinolone resistance caused 
by the S81F, S81Y, E85K, and V96A mutations primarily reflects a decrease in drug 
potency (i.e., affinity for the enzymes) rather than efficacy. Thus, it should be possible to 
overcome resistance if quinolones or quinolone-like drugs with higher affinities for the 
most common mutant type II enzymes can be developed. 
 As discussed above, quinolone resistance is most often associated with mutations 
at the serine and acidic residues. Although the underlying basis for quinolone resistance 
generated by these mutations is unknown, it has been suggested that it is related to the 
ability of quinolones to bind Mg2+ ions. Quinolones require divalent metal ions to unwind 
DNA,123,126,127 and it has long been assumed that Mg2+ is required to coordinate the 
interactions of quinolones in the enzyme-DNA complex.39,86,128 Based on the ability of 
ciprofloxacin to alter conformational equlibria in E. coli GyrA (but not GyrAS83W) in the 
presence of Mg2+ ions, Sissi et al.86 suggested that the serine was involved in mediating 
quinolone-Mg2+-protein interactions. This conclusion was supported by the 
crystallographic study that showed a bridging interaction between the quinolone and 
enzyme (mediated by a serine and acidic residue) that was facilitated by a Mg2+ ion 
chelated by the quinolone keto acid.43 
 If the above hypothesis is correct, then quinolone-like drugs that do not require 
the water-Mg2+ bridge might be relatively unaffected by mutations at these residues. 
Quinazolinediones are structurally similar to quinolones, but they lack the C3/C4 keto 
acid that is necessary to bind metal ions (Figure 14). Two quinazolinediones are known 
to display similar or better activity than quinolones against a variety of wild-type and 
quinolone-resistant Gram-positive and Gram-negative bacterial species in vitro, in 
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culture, and in a murine acute lethal Gram-positive infection model.105,122-124,129 
Therefore, a quinazolinedione was tested for activity against wild-type and quinolone-
resistant mutant B. anthracis topoisomerase IV. 
 8-Methyl-3’-(AM)P-dione induced DNA cleavage mediated by wild-type 
topoisomerase IV to a similar extent as did the quinolones (Figure 14 and Table 2). 
However, this drug was ~2.5 times more potent (as reflected by the CC3 value) than 
ciprofloxacin. In contrast to results with the quinolones, GrlAS81F, GrlAS81Y, GrlAE85K, 
and GrlAV96A topoisomerase IV displayed little to no resistance to the quinazolinedione 
(Figure 14 and Table 2). With GrlAS81F topoisomerase IV, the CC3 concentration for the 
quinazolinedione rose only 1.5-fold, and the level of maximal DNA cleavage was 
actually 36% higher than observed with the wild-type enzyme. With GrlAS81Y 
topoisomerase IV, both potency and efficacy were slightly better than those seen with the 
wild-type enzyme. With GrlAE85K topoisomerase IV, the CC3 for the quinazolinedione 
rose only 1.75-fold compared to wild-type (0.2 vs. 0.35 µM), and drug efficacy with the 
mutant enzyme was ~75% of that seen with wild-type topoisomerase IV (~22% vs. 29% 
maximal DNA cleavage). Finally, with GrlAV96A topoisomerase IV, the CC3 rose only 
1.25-fold, and drug efficacy was 20% higher than that seen with the wild-type enzyme. 
 The striking sensitivity of the quinolone-resistant topoisomerase IV enzymes to 8-
methyl-3’-(AM)P-dione is consistent with the hypothesis that the proposed water-Mg2+ 
bridge interaction that coordinates the bacterial type II enzyme with quinolones is a major 
determinant for drug action. Although structurally similar to quinolones, 
quinazolinediones appear to interact with type II topoisomerases independently of the 
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bridge interaction and represent quinolone-like drugs that retain high activity against the 
most common quinolone resistance mutations. 
 
Biochemical Basis for Quinolone Action and Resistance in Wild-type and Mutant 
Quinolone-Resistant Topoisomerase IV 
 Several experiments were carried out to further characterize the biochemical 
mechanism of quinolone resistance in B. anthracis topoisomerase IV and the differences 
between quinolones and quinazolinediones. First, sites of DNA cleaved by wild-type, 
GrlAS81F, and GrlAS81Y topoisomerase IV were examined in the presence of 
ciprofloxacin, levofloxacin, CP-115,953, and 8-methyl-3’-(AM)P-dione (Figure 16). 
Some differences in site utilization were seen, and overall levels of quinolone-induced 
DNA cleavage mediated by the mutant enzymes dropped. However, no major differences 
in cleavage site specificity were observed for any drug-enzyme combination. Although 
some DNA cleavage bands became very faint in the presence of quinolones and the 
resistant enzymes, these bands were visible at higher drug concentrations (not shown).  
 These findings indicate that the resistance of GrlAS81F and GrlAS81Y 
topoisomerase IV to quinolones and the ability of 8-methyl-3’-(AM)P-dione to overcome 
the resistance are not related to the selection of DNA cleavage sites by B. anthracis 
topoisomerase IV. They further suggest that drug-DNA interactions formed in the 
presence of the mutant enzymes are essentially those formed in the presence of wild-type 
topoisomerase IV (albeit weaker with quinolones) and that the quinazolinedione-cleavage 
complex interactions are similar to those established by quinolones. 
 The increased quinolone CC3 values for GrlAS81F, GrlAS81Y, GrlAE85K, and 
GrlAV96A topoisomerase IV suggest that quinolones bind less tightly to the mutant
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Figure 16. Effects of quinolones and 8-methyl-3’-(AM)P-dione on DNA cleavage site 
selection by wild-type, GrlAS81F, and GrlAS81Y B. anthracis topoisomerase IV. An 
autoradiogram of a polyacrylamide gel identifying DNA sites cleaved by the enzymes is 
shown. Reactions contained no enzyme (No topo), or topoisomerase IV in the presence of 
the indicated concentrations of Mg2+ or Ca2+, or ciprofloxacin, levofloxacin, CP-115,953, 
or 8-methyl-3’-(AM)P-dione. Mg2+ (10 mM) was used in all drug-containing reactions. 
The autoradiogram is representative of at least three independent experiments. 
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enzymes than to wild-type topoisomerase IV. This finding is consistent with previous 
binding and kinetic studies with serine mutants of E. coli gyrase and Staphylococcus 
aureus topoisomerase IV.119,124,125,130 In contrast, the high affinity of 8-methyl-3’-(AM)P-
dione for the mutant enzymes appears to be maintained. Therefore, the basis underlying 
these differences was explored by examining the ability of ciprofloxacin to compete with 
the quinazolinedione.  
 Competition assays took advantage of the fact that lower levels of DNA cleavage 
were observed in the presence of the quinolone. Therefore, the relative contributions of 
ciprofloxacin and 8-methyl-3’-(AM)P-dione to DNA cleavage were determined by 
comparing levels of scission generated in the presence of both drugs to the cleavage 
observed in the presence of either drug alone. Even at quinolone concentrations that were 
7.5 times higher than that of the quinazolinedione, ciprofloxacin contributed less than 
half of the drug-induced DNA cleavage (Figure 17). This finding suggests that 
ciprofloxacin is unable to compete effectively with 8-methyl-3’-(AM)P-dione for binding 
to GrlAS81F and GrlAS81Y topoisomerase IV-DNA complexes and provides further 
evidence that the mutation at Ser81 of B. anthracis topoisomerase IV has a greater impact 
on the affinity of the quinolone than the quinazolinedione for the enzymes. 
 Next, the ability of drugs to inhibit topoisomerase IV-mediated DNA religation 
was assessed. Although quinolones impair DNA religation mediated by type II 
topoisomerases, their effects range from modest (<2-fold) to strong (~10-fold), depending 
on the enzyme species and drug employed.87,109,125,131 In the presence of wild-type B. 
anthracis topoisomerase IV, quinolones and the quinazolinedione had a similar moderate 
effect on enzyme-mediated DNA religation, increasing t1/2 values by ~3-fold (as 
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Figure 17. Competition between ciprofloxacin and 8-methyl-3’-(AM)P-dione for B. 
anthracis topoisomerase IV. The ability of 0-150 µM ciprofloxacin to compete with 20 
µM 8-methyl-3’-(AM)P-dione for GrlAS81F and GrlAS81Y B. anthracis topoisomerase IV 
was determined using DNA cleavage assays. Both drugs were added to reaction mixtures 
simultaneously. The relative contribution of the quinazolinedione (left axis) to the total 
level of DNA cleavage was calculated as follows: (% DNA cleavage with both drugs − % 
DNA cleavage with ciprofloxacin only) ÷ (% DNA cleavage with quinazolinedione only 
− % DNA cleavage with ciprofloxacin only). The relative contribution of ciprofloxacin to 
the total level of DNA cleavage (1 minus the above equation) can be read from the right 
axis. Error bars represent the standard deviation of at least three independent 
experiments. 
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compared to reactions carried out in the absence of drug; Figure 18). However, the two 
drug classes had markedly different effects on religation mediated by the quinolone-
resistant Ser81 and Glu85 mutant topoisomerase IV enzymes. Whereas 8-methyl-3’-
(AM)P-dione maintained (or even increased) its ability to inhibit religation, very little 
inhibition was seen in the presence of quinolones (Figure 18). Notably, the 
quinazolinedione was used at 20 µM with the wild-type and mutant enzymes, while the 
quinolones were ten times more concentrated when used with the mutant enzymes than 
when used with wild-type (200 µM vs. 20 µM). These results imply that the Ser81 and 
Glu85 resistance mutations impair quinolone function as well as binding. In contrast to 
Ser81 and Glu85 mutations, the V96A mutation had little effect on the ability of either 
the quinolone (50 µM) or quinazolinedione (20 µM) to inhibit religation (Figure 18). 
 Finally, the effects of resistance mutations on the persistence of drug-induced 
cleavage complexes were determined. This was accomplished by establishing DNA 
cleavage-religation equilibria with wild-type or mutant topoisomerase IV in the presence 
of ciprofloxacin (20 µM with wild-type; 50 µM with GrlAV96A; 200 µM with Ser81 and 
Glu85 mutants) or 8-methyl-3’-(AM)P-dione (20 µM), diluting reaction mixtures 20-fold, 
and monitoring the decay of cleavage complexes over time (Figure 19). The t1/2 for DNA 
cleavage induced by ciprofloxacin dropped ~20-fold with the Ser81 and Glu85 mutant 
enzymes, while the drop seen with 8-methyl-3’-(AM)P-dione was (at most) ~30%. With 
the V96A mutant enzyme, the t1/2 for DNA cleavage induced by ciprofloxacin dropped 
only ~5-fold, but, with the quinazolinedione, it dropped ~40%. These findings indicate 
that quinolone resistance correlates with a decreased stability of the topoisomerase IV-
drug-DNA ternary complex, while the high sensitivity of the mutant quinolone-resistant 
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Figure 18. Effects of quinolones and 8-methyl-3’-(AM)P-dione on the DNA religation 
activities of wild-type, GrlAS81F, GrlAS81Y, GrlAE85K, and GrlAV96A topoisomerase IV 
from B. anthracis. Results for assays carried out in the absence of drugs or in the 
presence of ciprofloxacin or 8-methyl-3’-(AM)P-dione are shown for all enzymes. 
Results with levofloxacin are also shown for wild-type, GrlAS81F, and GrlAS81Y. 
Religation was assessed by monitoring the loss of double-stranded DNA breaks (linear 
product) over time. Cleavage at time zero was set to 100%. Quinolone concentrations 
were 20 µM in assays that examined wild-type topoisomerase IV and were increased to 
50 µM in assays that examined GrlAV96A and 200 µM in assays that examined the Ser81 
and Glu85 mutant enzymes. The concentration of 8-methyl-3’-(AM)P-dione was 20 µM 
in all assays. Reactions carried out in the absence of drugs replaced 5 mM Mg2+ with 1 
mM Ca2+ in order to achieve readily quantifiable levels of DNA cleavage. Error bars 
represent the standard deviation of at least three independent experiments. 
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Figure 19. Effects of ciprofloxacin and 8-methyl-3’-(AM)P-dione on the persistence of 
ternary enzyme-drug-DNA cleavage complexes formed with wild-type, GrlAS81F, 
GrlAS81Y, GrlAE85K, and GrlAV96A topoisomerase IV from B. anthracis. Initial DNA 
cleavage-religation reactions were allowed to come to equilibrium and were then diluted 
20-fold with DNA cleavage buffer. The persistence of cleavage complexes was assessed 
by monitoring the loss of double-stranded DNA breaks (linear product) over time. 
Cleavage at time zero was set to 100%. The concentration of ciprofloxacin (left panel) 
was 20 µM in assays that examined wild-type topoisomerase IV and was increased to 50 
µM in assays that examined GrlAV96A and 200 µM in assays that examined the Ser81 and 
Glu85 mutant enzymes. The concentration of 8-methyl-3-(AM)P-dione was 20 µM in all 
assays. Error bars represent the standard deviation of at least three independent 
experiments. 
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topoisomerase IV enzymes to the quinazolinedione correlates with the maintenance of a 
stable ternary complex.  
 
Summary of Conclusions 
 The GrlAS81F, GrlAS81Y, GrlAE85K, and GrlAV96A mutations in topoisomerase IV 
cause quinolone resistance by decreasing drug potency (i.e. drug-enzyme affinity). These 
mutations also impair the ability of quinolones to inhibit enzyme-mediated DNA 
religation and decrease the stability of ternary enzyme-drug-DNA cleavage complexes. 8-
Methyl-3’-(AM)P-dione is a quinolone-like drug that retains high activity against the 
quinolone-resistant mutant enzymes. Wild-type topoisomerase IV is also very sensitive to 
this compound, and its potency and efficacy against the wild-type enzyme actually 
exceed that of the quinolones. Presumbly, due to the lack of a C3/C4 keto acid group, this 
quinazolinedione interacts with the enzymes independently of the proposed water-metal 
ion bridge interaction, thus explaining how the drug maintains activity against quinolone-
resistant mutant topoisomerase IV enzymes. Unlike the quinolones, the quinazolinedione 
inhibits religation mediated by the mutant type II enzymes, interacts more tightly with 
these enzymes than does ciprofloxacin, and forms very stable cleavage complexes. 
Finally, topoisomerase IV cleaves DNA at the same set of sites (although at different 
relative frequencies) in the presence of quinolones and quinazolinediones, indicating that 
both drug classes interact with the enzyme-DNA cleavage complex in a similar manner. 
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CHAPTER V 
 
FUNCTIONAL EVIDENCE FOR A WATER-METAL ION BRIDGE  
MEDIATING THE MAJOR INTERACTION BETWEEN QUINOLONES AND  
BACILLUS ANTHRACIS TOPOISOMERASE IV 
 
Introduction 
 Quinolones have long been known to chelate a variety of divalent metal ions,132-
134 which have been hypothesized to enhance a number of drug functions.39,86,128,134,135 
For example, quinolones bind DNA and alter the conformation of E. coli GyrA but only 
in the presence of divalent metal ions.86,127,135 A recent crystallographic study43 suggested 
that quinolones interact with bacterial type II topoisomerases through a bridging, non-
catalytic Mg2+ ion that is in turn stabilized by four water molecules that are coordinated 
to the side chains of a serine and an acidic amino acid residue through hydrogen bonds 
(Figure 7). This serine and acidic amino acid are the two residues that are most 
commonly mutated in quinolone-resistant bacterial strains.18,36,37,39,49,77-83 Typically, in 
both laboratory and clinical isolates, alterations at the serine residue comprise >90% of 
the mutant pool, with changes at the acidic residue comprising the bulk of the other 
mutations.  
 Quinazolinediones lack the C3/C4 keto acid necessary to chelate metal ions. 
Presumably, they overcome quinolone resistance caused by serine or acidic residue 
mutations by interacting with the enzyme independently of metal ions. This observation 
is consistent with the water-metal ion bridge interaction hypothesis. However, the 
existence of the water-metal ion bridge and its role in mediating quinolone-topoisomerase 
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interactions has not been directly tested or functionally corroborated. A potential 
confounding issue is that type II topoisomerases require two divalent metal ions per 
active site to support DNA cleavage.24-26,42,120,136,137 One of these “catalytic” metal ions 
binds with high affinity to site A and mediates the chemistry of DNA scission and 
religation. The other binds with lower affinity to site B and appears to play a structural 
role aligning the double helix during these processes. In addition, B. anthracis 
topoisomerase IV is a promiscuous enzyme (as discussed in Chapter III) that can utilize a 
variety of metal ions in the DNA cleavage reaction. Thus, it was difficult to separate the 
requirement of a non-catalytic Mg2+ (or other divalent) ion for quinolone action from the 
requirement for catalytic ions. 
 Three approaches were used to test the validity of the water-metal ion bridge 
hypothesis. Experiments were carried out to determine whether quinolone action requires 
divalent metal ions, whether the serine and acidic residues anchor the proposed water-
metal ion bridge interaction, and how mutations in these two amino acids could affect the 
metal ion requirement. The quinazolinedione was tested alongside the quinolones 
because it maintains activity against quinolone-resistant mutant topoisomerase IV and 
appears to be a metal-ion-independent drug. 
 
Results and Discussion 
 
Metal Ion Requirements for Quinolone-induced DNA Cleavage 
 In order to establish whether quinolone function requires non-catalytic metal ions, 
it was necessary to segregate the functions of the catalytic and non-catalytic metal ions. 
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Therefore, a variety of divalent (and trivalent) cations were screened for the ability to 
support DNA cleavage mediated by wild-type B. anthracis topoisomerase IV in the 
absence of drugs or in the presence of ciprofloxacin or 8-methyl-3’-(AM)P-dione. Each 
metal ion was tested over a range of 50 µM to 10 mM and optimized for activity with the 
wild-type enzyme. Mg2+, Mn2+, Co2+, Sr2+, Ni2+, Pb2+, Al3+, Tb3+, and Eu3+ supported 
topoisomerase IV-mediated DNA cleavage under all three conditions (not shown). 
However, four divalent metal ions – Ca2+, Cd2+, Zn2+, and Ba2+ – supported DNA 
cleavage differentially. Although they supported basal enzyme activity and high levels of 
DNA cleavage in the presence of 8-methyl-3’-(AM)P-dione, each showed little or no 
ability to support DNA cleavage enhancement by ciprofloxacin (Figure 20; results with 
Ba2+ are not shown). These results strongly suggest that quinolones, but not 
quinazolinediones, require a non-catalytic divalent metal ion in order to induce DNA 
cleavage. 
 Ca2+, Cd2+, Zn2+, and Ba2+ have all been shown to complex with 
quinolones.133,134,138-141 Therefore, when chelated by ciprofloxacin, these ions likely 
cannot support the proper coordination geometry to form a functional water-metal ion 
bridge. However, an alternative interpretation is plausible. Sub-millimolar concentrations 
of metal ions were used in experiments because higher concentrations of Cd2+ and Zn2+ 
impaired enzyme activity and higher concentrations of Ca2+ and Ba2+ significantly raised 
basal levels of DNA cleavage. Thus, it is possible that they did not support ciprofloxacin-
induced DNA cleavage because the drug sequesters the divalent cations and prevents 
their use in the active site of the enzyme. Two controls indicate that this is not the case 
(Figure 20). First, no enhancement of DNA cleavage was observed at the lowest 
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Figure 20. Effects of alternative metal ions on drug-induced DNA cleavage mediated by 
wild-type B. anthracis topoisomerase IV. Assays were carried out with ciprofloxacin or 
8-methyl-3’-(AM)P-dione. The indicated divalent metal ions were substituted for the 
Mg2+ used in standard assays. Cd2+ (300 µM; top right) and Zn2+ (200 µM; bottom right) 
were utilized at the concentration that gave maximal enzyme-mediated DNA cleavage 
activity. Ca2+ was utilized at 250 µM (top left) or 1 mM (bottom left). Error bars 
represent the standard deviation of at least three independent experiments. 
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concentrations of ciprofloxacin (<50 µM) at which concentrations of metal ions would be 
more than sufficient to support the DNA cleavage reaction of topoisomerase IV. In 
contrast, significant levels of DNA cleavage were seen in the same concentration range of 
8-methyl-3’-(AM)P-dione. Second, experiments were repeated at 1 mM Ca2+. Even 
though drug effects were tempered by the high levels of basal (i.e., no drug) 
topoisomerase IV-mediated DNA cleavage, it is obvious that the quinazolinedione, but 
not the quinolone, further increases DNA scission.  
 
Roles of GrlA Ser81 and GrlA Glu85 in the Water-Metal Ion Bridge Interaction 
 The proposed water-metal ion bridge appears to be anchored to the topoisomerase 
through a serine and an acidic amino acid. These highly conserved residues, located in 
the A subunit of the enzyme, correspond to Ser81 and Glu85 in B. anthracis 
topoisomerase IV GrlA. If these residues play a role in the water-metal ion bridge 
interaction, their mutation may impact the variety of metal ions that can form a functional 
bridge and support quinolone activity. Therefore, experiments were carried out to identify 
metal ions that could distinguish between wild-type and mutant topoisomerase IV.  
 Metal ions that displayed optimal activity in the millimolar range were utilized for 
these studies to ensure that both the catalytic and non-catalytic sites were saturated over 
the drug range tested. Although Mg2+ (as well as Co2+; not shown) supported quinolone-
induced DNA cleavage mediated by wild-type, GrlAS81F, and GrlAE85K topoisomerase IV, 
Mn2+ and Ni2+ could only do so with the wild-type enzyme (Figure 21). In contrast, all 
four of these metal ions supported quinazolinedione-induced DNA cleavage with wild-
type and mutant topoisomerase IV (Figure 21, results with Co2+ are not shown). These 
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Figure 21. Effects of alternative metal ions on drug-induced DNA cleavage mediated by 
wild-type, GrlAS81F, and GrlAE85K topoisomerase IV from B. anthracis. Results are 
shown for cleavage mediated by the enzymes in the presence of ciprofloxacin (top) or 8-
methyl-3’-(AM)P-dione (bottom) and Mg2+ (left), Mn2+ (middle), or Ni2+ (right). Metal 
ions were utilized at the concentration that yielded maximal enzyme activity (10 mM for 
Mg2+ and Ni2+, 5 mM for Mn2+). Error bars represent the standard deviation of at least 
three independent experiments. 
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findings support the hypothesis that Ser81 and Glu85 play a role in quinolone-enzyme 
interaction. In addition, they suggest that mutation of either of the two amino acids that 
are proposed to anchor the bridge (and hence the quinolone) to the enzyme restricts the 
variety of divalent cations that can be used to form a functional water-metal ion bridge.  
 The serine and acidic residues are proposed to hydrogen bond with and stabilize 
the water molecules that fill the coordination sphere of the Mg2+ ion that is chelated by 
the quinolone keto acid. Therefore, mutation of these residues may decrease the ability of 
Mg2+ to bind and form the water-metal ion bridge. To determine whether the 
SerPhe/Tyr and GluLys mutations alter the affinity of metal ions in the proposed 
bridge, the Mg2+ dependence of quinolone- and quinazolinedione-induced topoisomerase 
IV-mediated DNA cleavage was analyzed.  
 The quinolone and quinazolinedione displayed similar requirements for Mg2+ 
when wild-type topoisomerase IV was employed; half-maximal and maximal DNA 
cleavage were observed at ~0.35 mM and ~1 mM Mg2+, respectively (Figure 22). In 
contrast, the two drugs displayed markedly different Mg2+ requirements for DNA 
cleavage mediated by GrlAS81F, GrlAS81Y, and GrlAE85K. While the metal ion utilization 
for 8-methyl-3’-(AM)P-dione with the mutant enzymes closely resembled that seen with 
the wild-type enzyme, ciprofloxacin required higher levels of Mg2+ to support DNA 
cleavage (Figure 22). In the presence of the SerPhe mutation, levels of Mg2+ required 
to generate half-maximal and maximal DNA cleavage increased to ~0.75 mM and ~2.5 
mM Mg2+, respectively, in the presence of the quinolone. The SerTyr mutation is a 
more conservative mutation than SerPhe because the side chains of both serine and 
tyrosine contain a terminal –OH group. However, levels of Mg2+ required by GrlAS81Y to 
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Figure 22. Effects of Mg2+ on DNA cleavage mediated by wild-type and quinolone-
resistant mutant topoisomerase IV from B. anthracis. Results are shown for 50 µM 
ciprofloxacin (left) and 10 µM 8-methyl-3’-(AM)P-dione (right) with the wild-type, 
GrlAS81F, GrlAS81Y, GrlAE85K, and GrlAV96A enzymes in the top panels. Results for 
GrlAE85A (with wild-type and GrlAE85K for comparison) are shown in the bottom panels. 
DNA cleavage for each drug-enzyme pair was normalized to 100% at 10 mM Mg2+ to 
facilitate direct comparisons. Error bars represent the standard deviation of at least three 
independent experiments. 
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generate half-maximal and maximal quinolone-induced DNA cleavage (~0.85 mM and 
~3.0 mM Mg2+) were actually slightly higher than those required by GrlAS81F. Finally, in 
the presence of the GluLys mutation, these values were ~0.66 mM and ~3.0 mM Mg2+ 
when the quinolone was utilized. The requirement for higher Mg2+ concentrations to 
support quinolone- but not quinazolinedione-induced DNA cleavage by the mutant 
enzymes provides further evidence for the water-metal ion bridge that is proposed to 
coordinate quinolone-topoisomerase IV binding as well as the roles of Ser81 and Glu85 
in anchoring the bridge to the enzyme. 
 The KD values for Mg2+ binding to metal ion sites A and B are ~0.1 mM and ~1 
mM, respectively, for E. coli topoisomerase IV.26 Because half-maximal DNA cleavage 
was observed at ~0.35 mM Mg2+ for both the quinolone and the quinazolinedione with 
wild-type B. anthracis topoisomerase IV, it is likely that this value reflects the affinity of 
metal ion B rather than the metal ion used to mediate quinolone-protein binding. This 
supposition implies that the affinity of the metal ion involved in the protein-water-Mg2+-
quinolone interaction is higher than that of active site metal ion B, and that the Mg2+-
quinolone interaction only becomes limiting in the presence of mutations (such as those 
at Ser81 and Glu85) that disrupt the coordination of the water-Mg2+ bridge. 
Consequently, it is probable that the GrlA S81F, S81Y, and E85K mutations in B. 
anthracis topoisomerase IV actually lower the affinity of the quinolone-bridging Mg2+ by 
more than the approximately two-fold effect seen in Figure 22. 
 The mutation of Glu85Lys introduces a positively charged amino acid side 
chain in the place of a negatively charged one. Especially in the context of the water-
metal ion bridge where this side chain participates in hydrogen bonding with water 
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molecules and is in close proximity to a positively charged metal ion, the effects on metal 
ion utilization seen with the GrlAE85K mutant topoisomerase IV may be the result of the 
nature of the mutation rather than the simple loss of the bridge anchor. For example, the 
positive charge on the lysine could alter quinolone binding by repelling the divalent metal 
ion that is chelated by the quinolone. To test for this possibility, the properties of 
GrlAE85A topoisomerase IV were examined. This enzyme displayed cleavage activities in 
the absence of drug that were similar to those of GrlAE85K (Figure 23). Furthermore, the 
effects of drugs on GrlAE85A topoisomerase IV paralleled those seen with the GluLys 
mutant enzyme (Figure 24). Ciprofloxacin was able to poison GrlAE85A topoisomerase IV 
at high drug concentrations, while the mutation did not have any significant effect on the 
ability of the quinazolinedione to enhance topoisomerase IV-mediated DNA cleavage. 
Finally, as seen with the GluLys mutation, GrlAE85A required an increased 
concentration of Mg2+ to support maximal levels of DNA cleavage in the presence of 
ciprofloxacin, but not in the presence of 8-methyl-3’-(AM)P-dione (Figure 22). 
 The GrlAV96A mutation in topoisomerase IV causes resistance to ciprofloxacin, 
albeit at a lower level than do the mutations at Ser81 and Glu85, and 8-methyl-3’-(AM)P-
dione maintains high activity against this mutant enzyme. Based on crystallographic 
studies,43 Val96 does not appear to participate in the water-metal ion bridge interaction. 
Therefore, this mutation should not affect the concentration of Mg2+ required to achieve 
maximal levels of quinolone-induced DNA cleavage. As expected, GrlAV96A 
topoisomerase IV required wild-type concentrations of Mg2+ to achieve maximal levels 
of DNA cleavage in the presence of both the quinolone and the quinazolinedione (Figure 
22). This finding provides further evidence that the serine and acidic residues act as the 
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Figure 23. DNA relaxation and cleavage activities of B. anthracis GrlAS81F/E85K 
topoisomerase IV. The catalytic activity of the doubly-mutated enzyme was determined 
by assessing its ability to relax negatively supercoiled pBR322 plasmid DNA (left). The 
ability of the enzyme to cleave negatively supercoiled plasmid DNA in the absence of 
drugs is shown on the right. Cleavage assays utilized 10 mM Ca2+ as the divalent metal 
ion. The abilities of GrlAE85A and GrlAS81F/E85A to cleave DNA in the absence of drugs 
are also shown. Results with wild-type and GrlAE85K are shown for comparison. Error 
bars represent the standard deviation of at least three independent experiments. 
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Figure 24. Effects of ciprofloxacin and 8-methyl-3’-(AM)P-dione on the DNA cleavage 
activities of GrlAE85A, GrlAS81F/E85K, and GrlAS81F/E85A B. anthracis topoisomerase IV. 
DNA cleavage mediated by the wild-type and GrlAE85K enzymes is shown for 
comparison. Titrations to 500 µM ciprofloxacin (left) and 20 µM 8-methyl-3’-(AM)P-
dione (right) are shown. The inset shows the maximum level of levofloxacin- and 
moxifloxacin-induced DNA cleavage generated by GrlAS81F/E85K topoisomerase IV at 500 
µM drug. The maximum level of cleavage induced by these drugs (at 20 µM) with wild-
type is shown for comparison. Error bars represent the standard deviation of at least three 
independent experiments. 
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protein anchors for the water-metal ion bridge. In addition, it suggests that target-
mediated quinolone resistance can be caused by mechanisms other than disruption of the 
water-metal ion bridge interaction. Because Val96 is located on the same α helix as Ser81 
and Glu85, one possibility is that it causes quinolone resistance by slightly repositioning 
the quinolone and the intact water-metal ion bridge so that the drug loses some ability to 
stabilize cleavage complexes. 
 The above findings strongly suggest that the GrlA S81F, S81Y, and E85K 
mutations in B. anthracis topoisomerase IV disrupt the water-Mg2+ bridge that mediates 
quinolone-protein binding in the cleavage complex. This conclusion supports the 
hypothesis that quinolone resistance results from the disruption of this critical quinolone-
protein interaction43 and also provides an explanation for the lack of quinazolinedione 
resistance seen with these mutant enzymes. 
 The increased Mg2+ concentration required to support ciprofloxacin-induced DNA 
cleavage by GrlAS81F, GrlAS81Y, and GrlAE85K topoisomerase IV suggests that the mutant 
proteins can still bind the quinolone-bridging Mg2+ but do so with diminished affinity. 
Furthermore, because DNA cleavage assays utilize 10 mM Mg2+, which is significantly 
above the saturating metal ion concentration seen for these mutant enzymes (~3 mM), the 
decreased potency of quinolones against the resistant topoisomerases cannot be attributed 
solely to decreased Mg2+ binding. Thus, it is likely that quinolones still interact with 
GrlAS81F, GrlAS81Y, and GrlAE85K topoisomerase IV through a water-Mg2+ bridge. 
However, because serine and glutamic acid residues appear to coordinate two of the four 
water molecules that contact the Mg2+ ion, the water-metal ion bridge formed with the 
mutant enzymes is likely altered and less stable. As a result, quinolones display a 
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decreased potency for DNA cleavage, exhibit a reduced ability to inhibit DNA religation, 
and form less stable cleavage complexes with the mutant enzymes. In contrast, because 
quinazolinediones presumably do not require the water-Mg2+ bridge to mediate their 
interactions with bacterial type II topoisomerases, mutation of the serine and glutamic 
acid residues has little effect on the ability of 8-methyl-3’-(AM)P-dione to inhibit 
enzyme-mediated DNA religation and form stable ternary enzyme-drug-DNA complexes. 
Taken together, these results support the conclusion that Ser81 and Glu85 play important 
roles in mediating quinolone-enzyme interactions by anchoring the water-metal ion 
bridge. 
 
Simultaneous Mutation of the Amino Acid Residues that Anchor the Water-Metal Ion 
Bridge Interaction 
 Ser81 or Glu85 mutant topoisomerase IV enzymes appear to interact with 
quinolones through a partially functional (or altered) water-metal ion bridge. This could 
account for the observation that these mutations cause quinolone resistance, but high 
concentrations of quinolone can induce wild-type levels of DNA cleavage mediated by 
the mutant enzymes. Therefore, to further explore the significance of the water-metal ion 
bridge in quinolone-topoisomerase interaction, GrlAS81F/E85K topoisomerase IV was 
characterized. This enzyme contains mutations at both of the residues that anchor the 
water-metal ion bridge to the protein. 
 The double mutant displayed catalytic and DNA cleavage activities that were 
similar to those of GrlAE85K topoisomerase IV (Figure 23). However, unlike results with 
the individual GrlAS81F and GrlAE85K mutants, ciprofloxacin and other clinically relevant 
quinolones displayed virtually no ability to enhance DNA cleavage mediated by 
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GrlAS81F/E85K topoisomerase IV, even at high drug concentrations (Figure 24). In contrast, 
8-methyl-3’-(AM)P-dione induced near wild-type levels of DNA cleavage with the 
double mutant (Figure 24).  
 The decreased potency of quinolones with the individual GrlAS81F and GrlAE85K 
mutants (Figure 14) strongly suggests that impaired bridge function decreases the ability 
of quinolones to bind in the cleavage complex. Because quinolones induced virtually no 
DNA cleavage enhancement with GrlAS81F/E85K topoisomerase IV, it was impossible to 
determine quinolone potency with the double mutant. Therefore, a competition 
experiment was used to assess the effects of the double mutation on quinolone affinity 
(Figure 25). Because structural studies indicate that the interaction domains of quinolones 
and quinazolinediones in the cleavage complex overlap almost completely,40-43 the ability 
of ciprofloxacin (0-500 µM) to compete out DNA cleavage mediated by GrlAS81F/E85K 
topoisomerase IV in the presence of 5 µM 8-methyl-3’-(AM)P-dione was determined. 
Even at a 100-fold molar excess of quinolone over quinazolinedione, little competition 
was observed (DNA cleavage dropped by ~20%). This result indicates that in the absence 
of the water-metal ion bridge, the relative affinity of ciprofloxacin [compared to 8-
methyl-3’-(AM)P-dione] for the topoisomerase IV-DNA complex decreases >100-fold. 
 The above results strongly suggest that the proposed water-metal ion bridge 
represents the major conduit by which ciprofloxacin and other clinically relevant 
quinolones interact with topoisomerase IV in the DNA cleavage complex. However, as 
discussed above, it is possible that the insertion of the positively charged lysine residue in 
place of Glu85 disrupts enzyme-quinolone interactions by a mechanism that reflects more 
than the simple loss of the glutamic acid anchor. Although this was not the case in the 
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Figure 25. Ability of ciprofloxacin to compete out DNA cleavage induced by 8-methyl-
3’-(AM)P-dione with GrlAS81F/E85K topoisomerase IV from B. anthracis. The 
quinazolinedione was utilized at a concentration of 5 µM. The quinolone and 
quinazolinedione were added to reactions simultaneously. Error bars represent the 
standard deviation of at least three independent experiments. 
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mutant topoisomerase IV enzyme containing a mutation only at the Glu85 residue, it is 
possible that the formation of a partially functional water-metal ion bridge facilitated by 
Ser81 obscured some effects of this GluLys mutation. Therefore, GrlAS81F/E85A 
topoisomerase IV was also examined. This mutant enzyme displayed DNA cleavage 
activities in the absence of drug that were similar to its Glu85Lys counterpart (Figure 
23). In addition, ciprofloxacin (even at high concentrations) was still unable to enhance 
DNA cleavage mediated by this double mutant, and the activity of the quinazolinedione 
was unaffected. 
 These results provide further functional evidence supporting the water-metal ion 
bridge model for quinolone-topoisomerase IV interactions. GrlAS81F/E85K cannot support 
the water-metal ion bridge interaction, even in a partially functional form. Thus, the 
double mutation abrogates the activity of ciprofloxcin against the enzyme, but has little 
effect on the activity of a quinazolinedione that interacts with the protein independently 
of the bridge. An important ramification of the water-metal ion bridge model is that the 
most important interaction between clinically relevant quinolones and their bacterial 
enzyme targets is mediated by the drug core (Figure 7). This may explain the tolerance 
for the structural diversity of substituents at the N1, C7, and C8 positions of the 
quinolone drug class. 
 
Summary of Conclusions 
 The water-metal ion bridge is the primary interaction between clinically relevant 
quinolones and bacterial type II topoisomerases. The highly conserved serine and acidic 
amino acid residues (Ser81 and Glu85 in B. anthracis GrlA) act as the anchor points for 
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coordination of the bridge to the enzyme. Mutation of either of these anchoring residues 
interferes with the formation of a fully functional bridge and results in a quinolone-
resistant topoisomerase IV enzyme. Simultaneous mutation of both the serine and acidic 
residue completely abolishes the function of the water-metal ion bridge, which results in 
an enzyme that is fully resistant to quinolone activity, even at high drug concentrations. 
The significance of the water-metal ion bridge interaction (which is facilitated by the 
quinolone core rather than substituents) to quinolone activity may explain how these 
drugs can tolerate structurally diverse substituents at the N1, C7, and C8 positions. 
Although the bridge plays a pivotal role in mediating quinolone activity, mutation of 
amino acid residues that do not participate in this water-metal ion interaction can still 
cause some level of quinolone resistance. Thus, target-mediated quinolone resistance can 
occur by a mechanism other than disruption of the bridge.  
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CHAPTER VI 
 
QUINOLONE INTERACTIONS WITH ESCHERICHIA COLI TOPOISOMERASE IV 
 
Introduction 
 The primary interaction between clinically relevant quinolones and B. anthracis 
(Gram-positive) topoisomerase IV is mediated through a water-metal ion bridge. The 
serine and acidic residues that anchor the bridge to the enzyme are highly conserved 
across the bacterial kingdom, suggesting that the water-metal ion bridge may be the 
primary interaction between quinolones and all bacterial type II topoisomerases. As a 
step toward establishing the bridge as a universal mechanism of quinolone-topoisomerase 
interaction, E. coli (Gram-negative) topoisomerase IV was examined. 
 Experiments utilized wild-type and quinolone-resistant ParCS80L and ParCE84K 
topoisomerase IV and evaluated the effects of quinolones and a quinazolinedione on their 
activities. The metal ion dependence of quinolone-induced DNA cleavage was also 
examined. Ser80 and Glu84 are equivalent to Ser81 and Glu85 of B. anthracis GrlA and 
are, thus, the amino acid residues that would anchor the water-metal ion bridge in this 
enzyme. Although topoisomerase IV appears to be the secondary target for quinolones in 
E. coli,46 the ParCS80L and ParCE84K mutations are commonly observed in quinolone-
resistant clinical isolates.80-83 The ParC Ser80Ile mutation is more common in the clinic 
than the Ser80Leu mutation,80-83 but ParCS80L was chosen for these studies due to it 
more often being utilized in the laboratory in previous studies on quinolone resistance in 
this species.46,117,142-144 
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Results and Discussion 
 
Enzymatic Activities of Wild-type and Quinolone-Resistant ParCS80L and ParCE84K  
Topoisomerase IV 
 As discussed in Chapter III, mutations in topoisomerase IV can cause quinolone 
resistance either by disrupting quinolone-enzyme interactions and causing a decrease in 
quinolone efficacy and/or potency, or by directly affect the enzyme, such as by causing it 
be unstable or less active. Therefore, the relaxation and cleavage activities of the wild-
type and quinolone-resistant ParCS80L and ParCE84K enzymes were first evaluated in the 
absence of drugs. 
 As expected, ParCS80L topoisomerase IV relaxed negatively supercoiled plasmid 
DNA at a rate that was nearly identical to that of the wild-type enzyme (Figure 26). 
ParCE84K was previously shown to have a significantly decreased rate of DNA 
relaxation,117 very similar to that of GrlAE85K from B. anthracis topoisomerase IV. 
Presumably, this mutation has the same effect on E. coli topoisomerase IV as it does on 
the B. anthracis enzyme and, thus, causes a defect in strand passage. For this reason, both 
mutant E. coli enzymes were examined for their ability to mediate DNA cleavage. 
 Wild-type and ParCS80L E. coli topoisomerase IV displayed similar abilities to 
cleave DNA in the absence of drugs (Figure 27). Unexpectedly, the Glu84Lys mutant 
enzyme displayed a DNA cleavage ability that was approximately half that of the wild-
type enzyme. Therefore, unlike in the B. anthracis enzyme, this mutation may cause 
quinolone resistance by affecting the activity of the enzyme, rather than (or in addition 
to) decreasing drug potency and/or efficacy. 
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Figure 26. Catalytic activities of wild-type and ParCS80L topoisomerase IV from E. coli. 
The ability of the enzymes to relax negatively supercoiled pBR322 plasmid DNA is 
shown. Error bars represent the standard deviation of at least three independent 
experiments. 
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Figure 27. DNA cleavage activities of wild-type, ParCS80L, and ParCE84K topoisomerase IV 
from E. coli. The ability of the enzymes to cleave negatively supercoiled pBR322 
plasmid DNA in the absence of drugs is shown. Assays were carried out in the presence 
of 2.5 mM CaCl2. Error bars represent the standard deviation of at least three independent 
experiments.  
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 As observed with B. anthracis topoisomerase IV, a number of different metal ions 
can support the cleavage activity of the wild-type E. coli enzyme (not shown). Therefore, 
this enzyme also appears to have a promiscuous catalytic metal ion usage profile. 
 
Effects of Ciprofloxacin and 8-Methyl-3’-(AM)P-dione on Wild-type and Quinolone- 
Resistant ParCS80L and ParCE84K Topoisomerase IV  
 To determine how the ParC Ser80Leu and Glu84Lys mutations cause 
quinolone resistance, the ability of ciprofloxacin to enhance DNA cleavage mediated by 
wild-type and mutant E. coli topoisomerase IV was assessed. As expected, ciprofloxacin 
displayed little ability to enhance DNA cleavage mediated by ParCS80L and ParCE84K as 
compared to the wild-type enzyme (Figure 28). However, in contrast to results with the 
equivalent B. anthracis enzymes, the E. coli mutant enzymes displayed little to no 
increase in ciprofloxacin-enhanced DNA cleavage, even at high drug concentrations 
(Figure 28). Based on these results, it appears that ParCS80L causes quinolone resistance 
in E. coli topoisomerase IV by decreasing both the potency and efficacy of the drug, 
while ParCE84K appears to cause resistance primarily through an efficacy effect. Although 
the ParCS80L and ParCE84K mutations seem to have somewhat different effects on 
quinolone activity than do the equivalent mutations in B. anthracis topisomerase IV, 
these mutant enzymes, as well as the wild-type enzyme, maintained sensitivity to 8-
methyl-3’-(AM)P-dione (Figure 28).  
 Because ciprofloxacin displayed no ability to enhance DNA cleavage mediated by 
ParCE84K topoisomerase IV, a competition experiment was carried out to determine 
whether the quinolone maintained any ability to bind to the mutant enzyme. In this
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Figure 28. Effects of ciprofloxacin and 8-methyl-3’-(AM)P-dione on the DNA cleavage 
activities of wild-type, ParCS80L, and ParCE84K topoisomerase IV from E. coli. Cleavage 
induced by clinically relevant concentrations of the quinolone (top) and quinazolinedione 
(bottom) are shown on the left. Maximal levels of cleavage induced by high 
concentrations of the drugs are shown on the right. Error bars represent the standard 
deviation of at least three independent experiments. Note that the ParCE84K enzyme was 
used at a 2.5-fold higher concentration than the wild-type and ParCS80L enzymes to 
account for its decreased basal enzyme activity seen in Figure 27. This allows direct 
comparisons between the three enzymes to be made. 
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experiment, the ability of ciprofloxacin (0-500 µM) to compete out cleavage induced by 
10 µM 8-methyl-3’-(AM)P-dione was determined. Even at a ten-fold excess of quinolone 
over quinazolinedione, approximately half of the quinazolinedione-induced cleavage 
complexes remained (Figure 29). Therefore, the Glu84Lys mutation not only prevents 
quinolones from enhancing enzyme-mediated DNA cleavage, but it also decreases their 
ability to interact with the enzyme. 
 Next, experiments were carried out to determine whether quinolones and the 
quinazolinedione increase the concentration of E. coli topoisomerase IV cleavage 
complexes by inhibiting enzyme-mediated DNA religation. Because ciprofloxacin was 
not able to enhance ParCE84K topoisomerase IV DNA cleavage, only the wild-type and 
ParCS80L enzymes were tested. Although less dramatic than results with B. anthracis 
topoisomerase IV, ciprofloxacin did slow the DNA religation rate of the wild-type 
enzyme as compared to the rate seen in the absence of drug (Figure 30). As expected, the 
rate of DNA religation mediated by ParCS80L in the presence of ciprofloxacin was 
significantly decreased and was nearly indistinguishable from the rate observed in the 
absence of drug (Figure 30). In contrast, the quinazolinedione slowed the rate of DNA 
religation mediated by both wild-type and ParCS80L E. coli topoisomerase IV (Figure 30). 
These results imply that the resistance mutation impairs quinolone, but not 
quinazolinedione, function. 
 Finally, the persistence of cleavage complexes formed by wild-type and ParCS80L 
topoisomerase IV in the presence of drugs was determined. Overall, the E. coli 
topoisomerase IV cleavage complexes (Figure 31) appear to be less stable than their B. 
anthracis topoisomerase IV counterparts (Figure 19). The t1/2 of wild-type E. coli 
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Figure 29. Ability of ciprofloxacin to compete out DNA cleavage induced by 8-methyl-
3’-(AM)P-dione with ParCE84K topoisomerase IV from E. coli. The quinazolinedione was 
utilized at a concentration of 10 µM. The quinolone and quinazolinedione were added to 
reactions simultaneously. Error bars represent the standard deviation of at least three 
independent experiments. 
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Figure 30. Effects of ciprofloxacin and 8-methyl-3’-(AM)P-dione on the DNA religation 
activities of wild-type and ParCS80L topoisomerase IV from E. coli. Results for assays 
carried out in the absence of drugs are also shown. Religation was assessed by 
monitoring the loss of double-stranded DNA breaks (linear product) over time. Cleavage 
at time zero was set to 100%. Drugs were used at 20 µM in all assays. Error bars 
represent the standard deviation of at least three independent experiments. 
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Figure 31. Effects of ciprofloxacin and 8-methyl-3’-(AM)P-dione on the persistence of 
ternary enzyme-drug-DNA cleavage complexes formed with wild-type and ParCS80L 
topoisomerase IV from E. coli. Initial DNA cleavage-religation reactions were allowed to 
come to equilibrium and were then diluted 20-fold with DNA cleavage buffer. The 
persistence of cleavage complexes was assessed by monitoring the loss of double-
stranded DNA breaks (linear product) over time. Cleavage at time zero was set to 100%. 
Drugs were used at 20 µM in all assays. Error bars represent the standard deviation of at 
least three independent experiments. 
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topoisomerase IV cleavage complexes formed in the presence of ciprofloxacin was very 
similar to that of complexes formed in the presence of 8-methyl-3’-(AM)P-dione (Figure 
31). As expected, the persistence of ParCS80L cleavage complexes formed in the presence 
of ciprofloxacin was significantly decreased as compared to wild-type (Figure 31). 
However, the mutant quinazolinedione-induced cleavage complexes were also much less 
stable than the equivalent wild-type cleavage complexes (Figure 31). Despite this 
decreased stability, the ParCS80L quinazolinedione-induced cleavage complexes were still 
more stable than those formed in the presence of the quinolone. Therefore, quinolone 
resistance caused by the Ser80Leu mutation correlates with a decreased stability of the 
topoisomerase IV-drug-DNA ternary complex. In addition, even though 8-methyl-3’-
(AM)P-dione can induce high levels of ParCS80L cleavage complexes, they are less stable 
than those formed by the wild-type enzyme in the presence of the quinazolinedione. 
 
Metal Ion Requirements for Quinolone-induced DNA Cleavage Mediated by Wild-type  
and ParCS80L Topoisomerase IV 
 To determine whether quinolone-enzyme interactions in E. coli topoisomerase IV 
are mediated by the water-metal ion bridge, a Mg2+ titration was carried out. The 
quinolone and quinazolinedione displayed similar requirements for Mg2+ when wild-type 
topoisomerase IV was employed; half-maximal and maximal DNA cleavage were 
observed at ~0.42 mM and ~1 mM Mg2+, respectively (Figure 32). In contrast, the two 
drugs displayed markedly different Mg2+ requirements for DNA cleavage mediated by 
ParCS80L. While the metal ion utilization for 8-methyl-3’-(AM)P-dione closely resembled 
that seen with the wild-type enzyme, ciprofloxacin required higher levels of Mg2+ to 
support DNA cleavage (Figure 32). Levels of Mg2+ required to generate half-maximal
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Figure 32. Effects of Mg2+ on DNA cleavage mediated by wild-type and ParCS80L 
topoisomerase IV from E. coli. Results are shown for 20 µM ciprofloxacin (left) and 20 
µM 8-methyl-3’-(AM)P-dione (right). DNA cleavage for each drug-enzyme pair was 
normalized to 100% at 2.5 mM Mg2+ to facilitate direct comparisons. Error bars represent 
the standard deviation of at least three independent experiments. 
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and maximal DNA cleavage rose to ~0.79 mM and ~2 mM Mg2+, respectively, in the 
presence of the quinolone. The requirement for higher Mg2+ concentrations to support 
quinolone- but not quinazolinedione-induced DNA cleavage by the mutant enzyme 
suggests that interactions between quinolones and E. coli topoisomerase IV are mediated 
by the water-metal ion bridge and that Ser80 plays a role in anchoring the bridge to the 
enzyme. 
 
Summary of Conclusions 
 ParCS80L and ParCE84K topoisomerase IV from E. coli are resistant to quinolones 
but, like the wild-type enzyme, are sensitive to 8-methyl-3’-(AM)P-dione. Both of these 
mutations have larger effects on quinolone efficacy than do the equivalent mutations in B. 
anthracis topoisomerase IV, and ciprofloxacin actually displayed no ability to enhance 
DNA cleavage mediated by ParCE84K. As seen with the B. anthracis Ser81 mutants, the 
ParC Ser80Leu mutation decreases the ability of ciprofloxacin to inhibit enzyme-
mediated DNA religation and also decreases the stability of quinolone-induced cleavage 
complexes. Moreover, it appears that the water-metal ion bridge is functional and a major 
point of interaction with quinolones in E. coli topoisomerase IV. Because the serine and 
acidic residues that anchor the bridge are highly conserved throughout the bacterial 
kingdom and the bridge interaction is functional in both a Gram-positive (B. anthracis) 
and Gram-negative (E. coli) topoisomerase IV, it appears that the water-metal ion bridge 
is not species-specific and is the major mechanism by which quinolones interact with all 
bacterial type II topoisomerases. 
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CHAPTER VII 
 
OVERCOMING TARGET-MEDIATED QUINOLONE RESISTANCE 
 
Introduction 
 Structural studies indicate that quinolones and quinazolinediones interact with 
topoisomerase IV in the same drug-binding pocket.41 Several functional studies have 
demonstrated that members of the quinazolinedione drug class can overcome quinolone 
resistance caused by mutations in the serine or acidic amino acid residue,105,107,123,124,129 
suggesting that the quinazolinedione core does not require the water-metal ion bridge to 
interact with bacterial type II topoisomerases. Consistent with this idea, the C2 carbonyl 
of quinazolinediones appears to form a hydrogen bond with a conserved arginine residue 
(Arg119 in B. anthracis GrlA).41,107 However, this interaction is expected to be weaker 
than the water-metal ion bridge interaction utilized by quinolones. Although 
quinazolinediones have been shown to maintain activity against resistant enzymes (and 
bacterial strains), they feature a 3’-(aminomethyl)pyrrolidinyl or 3’-
(aminoethyl)pyrrolidinyl group at the C7 position (Figure 33), which is not represented in 
any clinically used quinolone.105,107,123,124,129 Therefore, it is possible that 
quinazolinediones overcome resistance through the introduction of additional drug-
enzyme contacts mediated by the C7 substituent, rather than through interactions 
mediated by the drug core. 
 Although it appears that the quinazolinediones are a drug class that could be 
devloped to combat quinolone-resistant infections, there have been no studies examining 
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Figure 33. Structures of quinolones and quinazolinediones. Ciprofloxacin and 
moxifloxacin are clinically relevant quinolones. Ciprofloxacin contains a piperazinyl 
group at the C7 position. Moxifloxacin contains a diazabicyclononyl group at the C7 
position. 8-Methyl-3’-(AM)P-dione and 8-methyl-3’-(AE)P-dione are quinazolinediones 
that have been shown to overcome quinolone resistance caused by topoisomerase 
mutations. 8-Methyl-3’-(AM)P-dione contains a 3’-(aminomethyl)pyrrolidinyl group at 
the C7 position. 8-Methyl-3’-(AE)P-dione contains a 3’-(aminoethyl)pyrrolidinyl group 
at the C7 position. The two different C7 groups of these quinazolinediones are not 
represented in any clinically relevant quinolone. 
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the effects of these compounds on human type II topoisomerases. Some quinolones have 
long been known to have high activity against the human enzymes,87-90 so it is possible 
that some quinazolinediones may also have undesirable cross-reactivity.  
 To resolve these issues and provide further understanding of target-mediated 
quinolone resistance, a series of quinazolinediones and quinolones that contain clinically 
utilized groups or a 3’-(aminomethyl)pyrrolidinyl group at the C7 position were tested for 
activity against wild-type and quinolone-resistant GrlAS81F, GrlAS81Y, and GrlAE85K B. 
anthracis topoisomerase IV. These drugs were also tested with human topoisomerase IIα 
to determine how clinically relevant quinolones differentiate between the human and 
bacterial type II enzymes and to determine potential causes of cross-reactivity with the 
human enzymes. 
 
Results and Discussion 
 
Contributions of the Quinazolinedione Core vs. Substituents to Drug Activity Against 
Quinolone-Resistant Topoisomerase IV 
 To address the mechanism by which quinazolinediones overcome quinolone 
resistance, three series of quinazolinediones and quinolones that contained a piperazinyl, 
diazabicyclononyl, or 3’-(aminomethyl)pyrrolidinyl group at the C7 position (Figure 34) 
were tested for activity against wild-type and quinolone-resistant GrlAS81F, GrlAS81Y, and 
GrlAE85K topoisomerase IV. Each series also featured matched compounds that included a 
hydrogen, methyl, or methoxy group at the C8 position. 
 The first two series were based on the C7 substituents of ciprofloxacin (Figure 35) 
and moxifloxacin (Figure 36), respectively, which are in wide clinical use. As expected,
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Figure 34. Structures of matched quinolones and quinazolinediones used in Chapter VII. 
These compounds are based on the clinically relevant quinolones ciprofloxacin and 
moxifloxacin and the quinazolinedione 8-methyl-3’-(AM)P-dione that overcomes 
resistance caused by topoisomerase mutations. “Non-amino” quinazolinediones are 
identical to quinazolinediones except that they lack the N3 amino group. Table 1 contains 
the full chemical, library, and abbreviated names for these compounds. 
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Figure 35. Effects of a ciprofloxacin-based series of quinolones and quinazolinediones on 
the DNA cleavage activity of B. anthracis topoisomerase IV. The ability of wild-type, 
GrlAS81F, and GrlAS81Y topoisomerase IV to cleave negatively supercoiled pBR322 DNA 
in the presence of quinolones (top) or quinazolinediones (bottom) containing a C7 
piperazinyl group and a C8 hydrogen (left), methyl (middle), or methoxy (right) group is 
shown. Drug structures are shown in the corresponding panels. Error bars represent the 
standard deviation of at least three independent experiments. 
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Figure 36. Effects of a moxifloxacin-based series of quinolones and quinazolinediones on 
the DNA cleavage activity of B. anthracis topoisomerase IV. The ability of wild-type, 
GrlAS81F, and GrlAS81Y topoisomerase IV to cleave negatively supercoiled pBR322 DNA 
in the presence of quinolones (top) or quinazolinediones (bottom) containing a C7 
diazabicyclononyl group and a C8 hydrogen (left), methyl (middle), or methoxy (right) 
group is shown. Drug structures are shown in the corresponding panels. Error bars 
represent the standard deviation of at least three independent experiments. 
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all of the quinolones in both series displayed high activity against wild-type B. anthracis 
topoisomerase IV but decreased activity against the resistant Ser81 and Glu85 mutant 
enzymes. In contrast, the parallel quinazolinedione series displayed poor activity against 
both the wild-type and mutant enzymes. These findings strongly suggest that (at least in 
compounds that incorporate these clinically relevant C7 substituents) the 
quinazolinedione core does not form strong interactions with topoisomerase IV.   
 To test this conclusion, a series of quinazolinediones and quinolones that feature 
the 3’-(aminomethyl)pyrrolidinyl group at C7 were examined (Figure 37). Consistent 
with previous reports,105,107,124 all of the quinazolinediones in this series showed high 
activity against wild-type and mutant quinolone-resistant topoisomerase IV. 
Significantly, the parallel quinolone series displayed similar results and maintained high 
activity against the resistant enzymes. Thus, in the presence of the C7 3’-
(aminomethyl)pyrrolidinyl substituent, the drug core (quinolone vs. quinazolinedione) 
makes little difference. 
 Taken together, these results indicate that the quinazolinedione core does not 
interact with the enzyme through metal-ion-independent contacts. Rather, 
quinazolinediones are essentially quinolone derivatives that lack their most important 
interaction (mediated by the water-metal ion bridge) with the bacterial type II 
topoisomerases. Furthermore, the ability of these compounds to act against wild-type 
gyrase and topoisomerase IV and to overcome the most common forms of quinolone 
resistance (caused by the lack of bridge function) results primarily from interactions 
formed by the 3’-(aminomethyl)pyrrolidinyl (and related) substituent at C7. 
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Figure 37. Effects of an 8-methyl-3’-(AM)P-dione-based series of quinolones and 
quinazolinediones on the DNA cleavage activity of B. anthracis topoisomerase IV. The 
ability of wild-type, GrlAS81F, GrlAS81Y, and GrlAE85K topoisomerase IV to cleave 
negatively supercoiled pBR322 DNA in the presence of quinolones (top) or 
quinazolinediones (bottom) containing a C7 3’-(aminomethyl)pyrrolidinyl group and a 
C8 hydrogen (left), methyl (middle), or methoxy (right) group is shown. Drug structures 
are shown in the corresponding panels. Error bars represent the standard deviation of at 
least three independent experiments. 
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 In addition to the C7 group, the substituent at C8 appears to make a minor 
contribution to the activity of both quinolones and quinazolinediones against the mutant 
enzymes (Figures 35-37). Generally, the inclusion of a methyl or methoxy group slightly 
enhances activity (methyl ≥ methoxy > hydrogen) against the mutant enzymes. These 
substituents had little effect against wild-type topoisomerase IV. 
 Finally, the effects of the N3 amino group on quinazolinedione activity were 
examined (Figure 38). The loss of the group decreased the activities of compounds with a 
C7 piperazinyl or diazabicyclononyl group toward wild-type and mutant topoisomerase 
IV by ~50%. In contrast, in the presence of the C7 3’-(aminomethyl)pyrrolidinyl 
substituent, the loss of the N3 amino group had little effect on the activity of the 
quinazolinedione against topoisomerase IV. These differential effects of the N3 group 
may reflect the increased affinity of the 3’-(aminomethyl)pyrrolidinyl group for B. 
anthracis topoisomerase IV. 
 
Interactions of Clinically Relevant Quinolones with Human Topoisomerase IIα 
 Clinically relevant quinolones, such as ciprofloxacin and moxifloxacin, display 
very little activity against human type II topoisomerases, even at concentrations well 
beyond therapeutic doses (Figure 39). However, the basis for this discrimination is not 
known. As discussed above, the primary interaction between clinically relevant 
quinolones and bacterial type II enzymes is mediated through the water-metal ion bridge. 
Unlike gyrase and topoisomerase IV, human topoisomerase IIα and IIβ lack the serine 
and acidic amino acid residues that anchor the bridge. In the α isoform, these residues are 
both methionine (Figure 39), and, in the β isoform, they are a glutamine and a 
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Figure 38. Effects of quinazolinediones lacking the N3 amino group on the DNA 
cleavage activity of B. anthracis topoisomerase IV. The ability of wild-type, GrlAS81F, 
and GrlAS81Y topoisomerase IV to cleave negatively supercoiled pBR322 DNA in the 
presence of “non-amino” quinazolinediones containing a C8 methyl group and a C7 
piperazinyl (left), diazabicyclononyl (middle), or 3’-(aminomethyl)pyrrolidinyl (right) 
group is shown. Results with 8-methyl-3’-(AM)P-NA-dione and GrlAE85K topoisomerase 
IV are also shown. Drug structures are shown in the corresponding panels. Error bars 
represent the standard deviation of at least three independent experiments. 
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Figure 39. Effects of ciprofloxacin, moxifloxacin, and their matched quinazolinediones 
on the DNA cleavage activities of wild-type and mutant (hTop2AM762S/M766E) human 
topoisomerase IIα. A sequence alignment of wild-type B. anthracis GrlA and human 
topoisomerase IIα is shown at the top. The methionine residues in the human enzyme that 
correspond to the serine and glutamic acid residues (red) that coordinate the water-metal 
ion bridge in B. anthracis topoisomerase IV were mutated to those seen in the bacterial 
enzyme. The effects of ciprofloxacin and cipro-dione (left) and moxifloxacin and moxi-
dione (right) on the DNA cleavage activities of wild-type and mutant human 
topoisomerase IIα are shown. Error bars represent the standard deviation of at least three 
independent experiments. 
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methionine. Therefore, the loss of the bridge anchors in topoisomerase IIα and IIβ could 
account for the discrimination between bacterial and human type II enzymes by clinically 
relevant quinolones. 
 To test this hypothesis, Met762 and Met766 in topoisomerase IIα were mutated to 
a serine and glutamic acid (hTop2AM762S/M766E), respectively, which are the residues in B. 
anthracis topoisomerase IV that coordinate quinolones through the water-metal ion 
bridge (Figure 39). In contrast to results with the wild-type human enzyme, both 
ciprofloxacin and moxifloxacin displayed concentration-dependent activity against 
hTop2AM762S/M766E, increasing levels of DNA cleavage ≥4-fold over the range examined 
(Figure 39). Consistent with these results, an earlier study reported that converting amino 
acid residues in this region of topoisomerase IIα to those seen in E. coli gyrase 
(M762S/S763A/M766D) enhanced the ability of ciprofloxacin to inhibit DNA relaxation 
catalyzed by the triply mutated enzyme.145 The fact that introducing bridge-coordinating 
amino acid residues sensitizes topoisomerase IIα to clinically relevant quinolones 
suggests that the wild-type human enzyme cannot support the water-metal ion bridge and 
(in some respects) is the equivalent of a quinolone-resistant topoisomerase IV. 
 As a control, the activities of cipro-dione and moxi-dione, which cannot support 
the water-metal ion bridge, against the wild-type and hTop2AM762S/M766E enzymes were 
assessed (Figure 39). These compounds are identical to ciprofloxacin and moxifloxacin, 
except that they utilize the quinazolinedione core rather than the quinolone core. Neither 
of the two compounds increased DNA cleavage mediated by the wild-type or mutant 
human enzyme. This finding further supports the conclusion that the enhanced activities 
of ciprofloxacin and moxifloxacin with hTop2AM762S/M766E are due to water-metal ion 
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interactions coordinated by the quinolone core, as opposed to interactions with the C7 or 
other substituents.  
 Taken together, the above results provide strong evidence that wild-type 
topoisomerase IIα cannot anchor the water-metal ion bridge, which explains why 
clinically relevant quinolones display little activity against the human enzymes. 
 
Effects of the C7 3’-(Aminomethyl)pyrrolidinyl Substituent on the Activity of Compounds 
Against Human Topoisomerase IIα 
 Quinolones that display high activity against eukaryotic type II topoisomerases 
have been reported.87-90 To this point, CP-115,955 and CP-115,953 increase DNA 
cleavage mediated by human topoisomerase IIα (Figure 40) to a greater extent than does 
the widely prescribed anticancer drug etoposide.146-149 CP-115,955 differs from 
ciprofloxacin only by the substitution of a 4’-hydroxyphenyl ring for the piperazinyl ring 
at the C7 position. This finding strongly suggests that quinolone interactions with human 
type II topoisomerases can be driven by the C7 substituent. 
 The interactions of CP-115,955 with topoisomerase IIα parallel those of 
compounds with the C7 3’-(aminomethyl)pyrrolidinyl substituent with quinolone-
resistant B. anthracis topoisomerase IV. In the absence of the water-metal ion bridge 
necessary for interactions with clinically relevant quinolones, these compounds still 
display high activity against the human and bacterial type II enzymes, respectively. This 
finding raises the possibility that compounds containing the C7 3’-
(aminomethyl)pyrrolidinyl substituent might display undesirable cross-reactivity against 
human type II topoisomerases. With either a quinazolinedione or a quinolone that 
contained a C8 methyl group, compounds that included the C7 
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Figure 40. Effects of 8-methyl-3’-(AM)P-dione and 8-methyl-3’-(AM)P-FQ on the DNA 
cleavage activity of human topoisomerase IIα. These compounds contain a 3’-
(aminomethyl)pyrrolidinyl group at the C7 position and a methyl group at the C8 
position. Results for moxifloxacin, ciprofloxacin, CP-115,955, CP-115,953, and 
etoposide are shown for comparison. Error bars represent the standard deviation of at 
least three independent experiments. 
 
112 
 
3’-(aminomethyl)pyrrolidinyl substituent displayed high activity against topoisomerase 
IIα (Figure 40). This finding implies that the ability to design quinolones or related drugs 
that overcome resistance in bacterial gyrase or topoisomerase IV may be hampered by 
cross-reactivity with the human enzymes. Therefore, a major challenge in designing such 
drugs is the identification of substituents that support activity against bacterial, but not 
human, type II topoisomerases. 
 
Defining Substituents on Quinolones and Quinazolinediones that Overcome Drug 
Resistance but Differentiate between B. anthracis Topoisomerase IV and Human 
Topoisomerase IIα 
 Although the C7 group appears to dominate interactions between quinolones or 
quinazolinediones and drug-resistant B. anthracis topoisomerase IV, the substituents at 
C8 (in both drug classes) and N3 (in quinazolinediones) appear to modulate drug activity 
to some extent (Figures 35-38).  
 With regard to quinolone interactions, human topoisomerase IIα largely mimics a 
drug-resistant topoisomerase IV mutant. Therefore, in an effort to identify compounds 
with potent activity against wild-type and quinolone-resistant topoisomerase IV (but low 
activity against human type II enzymes) the effects of C8 and N3 substituents on drug 
activity against topoisomerase IIα were examined. All of the quinolones and 
quinazolinediones tested contained a C7 3’-(aminomethyl)pyrrolidinyl substituent and 
displayed high activity against wild-type and quinolone-resistant B. anthracis 
topoisomerase IV (Figures 37 and 38).  
 The nature of the groups at C8 and N3 had a larger influence on drug activity 
against topoisomerase IIα than they did against topoisomerase IV. The activities of 
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compounds with C8 methoxy groups were somewhat lower than the corresponding 
compounds with C8 methyl groups (Figure 41), although they still displayed reasonable 
activity against the human enzyme. In contrast, removal of the C8 or N3 substituent 
resulted in 3’-(aminomethyl)pyrrolidinyl-quinolones or -quinazolinediones that were able 
to differentiate between the bacterial and human enzymes. One quinolone and two 
quinazolinediones (Figure 42) that displayed high activity against wild-type and mutant 
topoisomerase IV (Figures 37 and 38) showed virtually no activity against topoisomerase 
IIα at drug concentrations below 100 µM (Figure 42). This concentration is well above 
the therapeutic window for clinically used quinolones.150 Therefore, it is possible to 
design quinolones and related drugs that display high activity against the most common 
forms of quinolone-resistant topoisomerase IV but do not cross-react with human 
topoisomerase IIα.  
 The ability of quinolones (and related drugs) to differentiate between bacterial 
and human type II topoisomerases is critical to the clinical efficacy of this drug class. 
Clinically relevant quinolones discriminate between wild-type enzymes by utilizing a 
water-metal ion bridge in bacterial systems that cannot be supported in human systems. 
The key to the discrimination between drug-resistant topoisomerase IV and wild-type 
topoisomerase IIα relies on the relative dominance of the C7 group in mediating drug 
interactions. In the presence of a C7 3’-(aminomethyl)pyrrolidinyl substituent, the 
contributions of the C8 and N3 groups to drug-topoisomerase IV interactions are 
relatively unimportant. In contrast, these groups appear to be a determining factor in 
whether a compound has activity against human topoisomerase IIα. That being said, the 
C7 3’-(aminomethyl)pyrrolidinyl substituent still seems to be the most important of the 
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Figure 41. Effects of 8-methoxy-3’-(AM)P-dione and 8-methoxy-3’-(AM)P-FQ on the 
DNA cleavage activity of human topoisomerase IIα. These compounds contain a 3’-
(aminomethyl)pyrrolidinyl group at the C7 position and a methoxy group at the C8 
position. Results for the C8 methyl versions of these compounds are shown for 
comparison. Error bars represent the standard deviation of at least three independent 
experiments. 
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Figure 42. Effects of 8-methyl-3’-(AM)P-dione-based compounds on the cleavage 
activity of human topoisomerase IIα. The ability of the human type II enzyme to cleave 
negatively supercoiled pBR322 DNA in the presence of a quinolone and a 
quinazolinedione containing a C7 3’-(aminomethyl)pyrrolidinyl group and a hydrogen at 
C8 and a “non-amino” quinazolinedione containing a C7 3’-(aminomethyl)pyrrolidinyl 
group and a C8 methyl group are shown. The structures of these compounds (which 
overcome quinolone resistance in mutant B. anthracis topoisomerase IV) are at the right. 
Results with etoposide are shown for comparison. Error bars represent the standard 
deviation of at least three independent experiments. 
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three. To this point, quinolones or N3-amino-quinazolinediones that include the C7 
groups of ciprofloxacin or moxifloxacin display low activity against the human type II 
enzyme, even in the presence of a methyl or methoxy group at C8 (not shown). 
 A series of competition experiments was carried out to determine the mechanistic 
contributions of the C7 and C8 substituents and the quinolone vs. quinazolinedione core 
to drug interactions with topoisomerase IIα. In these experiments, the ability of 
compounds to compete out DNA cleavage induced by 50 µM 8-methyl-3’-(AM)P-FQ 
was assessed (Figure 43). The IC50 for 8-H-3’-(AM)P-FQ was ~50 µM, suggesting that 
the C8 group is important for drug efficacy but does not contribute significantly to 
binding. Presumably, interactions with the C8 methyl group help to properly position the 
drug in the cleavage complex. A similar result was seen with 8-H-3’-(AM)P-dione, 
suggesting that differences in levels of DNA cleavage induced by quinolones and 
quinazolinediones do not reflect changes in drug binding. In contrast, the IC50 for 
ciprofloxacin [which differs from 8-H-3’-(AM)P-FQ only at the C7 position] was nearly 
6-fold higher (~280 µM). This finding provides strong evidence that the C7 substituent 
plays an important role in driving binding interactions between drugs and the human 
enzyme. 
 
Summary of Conclusions 
 Because the quinazolinedione core does not appear to mediate any strong 
interactions with the bacterial type II topoisomerases, quinazolinediones are essentially 
quinolones that lack their most important interaction with the bacterial enzymes. Thus, 
quinazolinediones that display high activity against wild-type and quinolone-resistant 
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Figure 43. Ability of ciprofloxacin, 8-H-3’-(AM)P-FQ, and 8-H-3’-(AM)P-dione to 
compete out DNA cleavage induced by 50 µM 8-methyl-3’-(AM)P-FQ with human 
topoisomerase IIα. 8-Methyl-3’-(AM)P-FQ and the competing drug were added to 
reactions simultaneously. Initial levels of DNA cleavage (i.e., in the absence of 
competitor) were set to 1.00 to facilitate comparisons. Error bars represent the standard 
deviation of at least three independent experiments. 
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type II topoisomerases do so primarily by establishing novel interactions with the 
enzymes through the C7 substituent. The N3 and C8 substituents make minor 
contributions to the interactions of these drugs with the bacterial enzymes. Clinically 
relevant quinolones display poor activity against human topoisomerase IIα because the 
enzyme cannot support drug interactions mediated by the water-metal ion bridge. 
Unfortunately, the inclusion of C7 (and other) substituents that allow quinazolinediones 
to overcome quinolone resistance in bacterial type II enzymes can lead to cross-reactivity 
with human topoisomerase IIα (Figure 44). Therefore, a major challenge in designing 
quinolone-like drugs that overcome target-mediated resistance lies in the ability to 
identify substituents that mediate strong interactions with the bacterial, but not the 
human, type II enzymes. Three such compounds – 8-H-3’-(AM)P-FQ, 8-H-3’-(AM)P-
dione, and 8-methyl-3’-(AM)P-NA-dione – have been identified. Levofloxacin (which 
contains a C7 group similar to that of ciprofloxacin but has a tricyclic drug core) shows 
very little ability to compete out DNA cleavage induced by 8-methyl-3’-(AM)P-FQ with 
human topoisomerase IIα (not shown). Therefore, it may also be possible to use a 
tricyclic quinolone core (like that of levofloxacin) to selectively target the bacterial type 
II topoisomerases. For example, substituting a 3’-(aminomethyl)pyrrolidinyl group for 
the N-methylpiperazinyl C7 group on levofloxacin may result in a quinolone that has 
high activity against quinolone-resistant bacterial enzymes (due to drug-enzyme 
interactions mediated by the C7 group) but no activity against the human enzyme (due to 
selectivity provided by the cyclization between the C8 and N1 substituents).  
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Figure 44. Roles of substituents and core elements of quinolones and quinazolinediones 
in mediating drug activity against bacterial and human type II topoisomerases. 
Quinolones: The binding of clinically relevant quinolones to topoisomerase IV is 
mediated primarily through the water-metal ion bridge. The binding of quinolones that 
overcome resistance is mediated primarily by the C7 substituent. Quinolone binding to 
human topoisomerase IIα is also mediated by the C7 substituent. The C8 group affects 
the ability of quinolones to act against the human type II enzyme but is not required for 
drug binding. Quinazolinediones: Interactions between quinazolinediones and 
topoisomerase IV (wild-type and quinolone-resistant) are mediated through the C7 
substituent. The effects of the C7 and C8 substituents on quinazolinedione activity 
against topoisomerase IIα are the same as described for the quinolones. The N3 amino 
group plays a role in the binding of quinazolinediones to the human enzyme. 
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CHAPTER VIII 
 
QUINOLONES WITH POTENTIAL AS ANTICANCER CHEMOTHERAPEUTICS 
 
Introduction 
 Human type II topoisomerases are targeted by various anticancer agents, 
including etoposide, doxorubicin, mitoxantrone, and amsacrine.22,34 These drugs function 
similarly to the quinolones in that they enhance topoisomerase-mediated DNA cleavage 
and ultimately kill cells by increasing the concentration of double-stranded DNA breaks 
to the point that they overwhelm repair processes and trigger apoptosis.22,34 
 Some quinolones, including CP-115,953 and CP-115,955, have high activity 
against both human and bacterial type II topoisomerases.87-90 However, little is known 
regarding the similarities and differences between their interactions with the human and 
bacterial enzymes. To explore how these drugs interact with type II topoisomerases, a 
series of CP-115,955-based compounds was tested with wild-type and quinolone-
sensitive M762S/M766E human topoisomerase IIα and wild-type and quinolone-resistant 
GrlAS81F and GrlAS81Y B. anthracis topoisomerase IV. Compounds that were examined 
included quinolones, quinazolinediones, and non-amino-quinazolinediones containing a 
4’-hydroxyphenyl substituent at the C7 position and a C8 hydrogen, methyl, or methoxy 
group. A subset of these compounds was also tested in human CEM cells to determine 
whether the activities observed in vitro were paralleled in the context of the cell. 
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Results and Discussion 
 
Effects of CP,115-955-based Compounds on DNA Cleavage Mediated by Wild-type and  
Quinolone-Resistant GrlAS81F and GrlAS81Y Topoisomerase IV from B. anthracis 
 CP-115,955 is an experimental quinolone that differs from ciprofloxacin only by 
the inclusion of a 4’-hydroxyphenyl group in place of the piperazinyl moiety at the C7 
position. As discussed in Chapter VII, this drug (and CP-115,953, which differs from CP-
115,955 only by the inclusion of a fluorine at the C8 position) has high activity against 
both bacterial and human type II topoisomerases. Therefore, much like the 3’-
(aminomethyl)pyrrolidinyl group, it may have cross-reactivity with the human system 
due to the C7 4’-hydroxyphenyl mediating strong interactions with both enzymes. To test 
this hypothesis, the effects of a series of quinolones, quinazolinediones, and non-amino-
quinazolinediones on DNA cleavage mediated by wild-type and quinolone-resistant 
topoisomerase IV were examined. 
 As expected, all three quinolones showed high activity against wild-type B. 
anthracis topoisomerase IV (Figure 45). However, the GrlAS81F and GrlAS81Y mutant 
enzymes were resistant to these compounds (Figure 45). This finding suggests that CP-
115,955 (and related quinolones) interacts with bacterial type II topoisomerases through 
the water-metal ion bridge and that the C7 4’-hydroxyphenyl group, like the C7 groups of 
the clinically relevant quinolones, mediates little interaction with the bacterial enzymes.  
 As observed with the quinazolinediones containing a clinically relevant C7 group 
(discussed in Chapter VII), CP-115,955-based quinazolinediones showed decreased 
activity against both wild-type and mutant topoisomerase IV (Figure 45). In addition, the 
removal of the N3 amino group decreased the activity of these quinazolinediones by 
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Figure 45. Effects of a CP-115,955-based series of quinolones, quinazolinediones, and 
non-amino-quinazolinediones on the DNA cleavage activity of B. anthracis 
topoisomerase IV. The ability of wild-type, GrlAS81F, and GrlAS81Y topoisomerase IV to 
cleave negatively supercoiled pBR322 DNA in the presence of quinolones (top), 
quinazolinediones (middle), or non-amino-quinazolinediones (bottom) containing a C7 
4’-hydroxyphenyl group and a C8 hydrogen (left), methyl (middle), or methoxy (right) 
group is shown. Representative drug structures are shown in the left panels. Error bars 
represent the standard deviation of at least three independent experiments. 
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≥50% (Figure 45). Finally, the inclusion of a C8 methyl or methoxy group somewhat 
enhanced the activity of the compounds against the bacterial enzymes (Figure 45). 
 Taken together, these results indicate that CP-115,955-based quinolones and 
quinazolinediones interact with topoisomerase IV in much the same way that quinolones 
and quinazolinediones containing clinically relevant C7 groups [rather than a C7 3’-
(aminomethyl)pyrrolidinyl group] interact with the bacterial enzyme. The primary 
interaction between the quinolones and the bacterial type II enzymes is the water-metal 
ion bridge, the quinazolinediones are essentially quinolones that lack their most important 
interaction with the enzymes, and the C8 and N3 substituents display some ability 
modulate the activities of the compounds. 
 
Effects of CP-115,955-based Compounds on Wild-type and Quinolone-sensitive  
M762S/M766E Human Topoisomerase IIα 
 To explore the interactions between CP-115,955-based compounds and human 
type II topoisomerases, the drugs were first tested for their ability to enhance DNA 
cleavage mediated by wild-type topoisomerase IIα. As expected, all three quinolones 
displayed high activity against the enzyme (Figure 46). This activity actually exceeded 
that of the anticancer drug etoposide. As observed with 3’-(aminomethyl)pyrrolidinyl-
containing compounds, the activities of CP-115,955-based quinazolinediones against 
topoisomerase IIα were reduced as compared to their quinolone counterparts (Figure 46). 
In addition, removal of the N3 amino group further decreased the activities of the 
quinazolinediones (Figure 46). 
 Combined with observations from Chapter VII, these results indicate that 
quinolones tend to have higher activity against all type II topoisomerases than do 
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Figure 46. Effects of a CP-115,955-based series of quinolones, quinazolinediones, and 
non-amino-quinazolinediones on the DNA cleavage activity of human topoisomerase IIα. 
The ability of the enzyme to cleave negatively supercoiled pBR322 DNA in the presence 
of quinolones, quinazolinediones, or non-amino-quinazolinediones containing a C7 4’-
hydroxyphenyl group and a C8 hydrogen (left), methyl (middle), or methoxy (right) 
group is shown. Results with etoposide, ciprofloxacin, and moxifloxacin are shown for 
comparison. Error bars represent the standard deviation of at least three independent 
experiments. 
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quinazolinediones. The basis for this difference of activity in the bacterial enzymes can 
be attributed to the loss of the water-metal ion bridge interaction upon changing from a 
quinolone core to a quinazolinedione core. However, because wild-type human type II 
topoisomerases cannot mediate the bridge interaction, the basis for this difference in 
activity in the human system is not clear. Presumably, either a portion of the quinolone 
core mediates a weak, non-bridge interaction with the enzyme or a portion of the 
quinazolinedione core sterically clashes with the enzyme. 
 In contrast to results with the 3’-(aminomethyl)pyrrolidinyl series of quinolones 
and quinazolinediones, the inclusion of a C8 group in the CP-115,955 series decreased, 
rather than increased, the activities of the compounds against human topoisomerase IIα 
(Figure 46). These results suggest that a very specific interaction occurs between the C7 
4’-hydroxyphenyl group and the enzyme and the presence of a C8 group can alter this 
interaction. The C8 group could alter C7-enzyme interactions by changing the electronics 
and/or planarity of the compounds. It is also possible that the 4’-hydroxyphenyl group 
slips into a tight pocket in the enzyme, thus causing steric crowding between the C8 
methyl or methoxy group and the protein. 
 Next, competition experiments were carried out to determine why some 
compounds that contained a C7 4’-hydroxyphenyl group did not have activity against 
human topoisomerase IIα. Thus, the ability of ciprofloxacin, 8-methoxy-955-dione, and 
955-NA-dione to compete out cleavage induced by 20 µM CP-115,955 was assessed.  
 Ciprofloxacin displayed very little ability to compete with CP-115,955 for 
binding to the human enzyme (Figure 47). This indicates that there is a strong interaction 
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Figure 47. Ability of ciprofloxacin, 8-methoxy-955-dione, and 955-NA-dione to compete 
out DNA cleavage induced by 20 µM CP-115,955 with human topoisomerase IIα. CP-
115,955 and the competing drug were added to reactions simultaneously. Initial levels of 
DNA cleavage (i.e., in the absence of competitor) were set to 1.00 to facilitate 
comparisons. Error bars represent the standard deviation of at least three independent 
experiments. 
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between topoisomerase IIα and the C7 4’-hydroxyphenyl group of CP-115,955 that 
cannot be facilitated by the C7 piperazinyl moiety of ciprofloxacin. 
 8-Methoxy-955-dione and 955-NA-dione displayed similar and weak abilities to 
compete with CP-115,955 (Figure 47). Results with 8-methoxy-955-dione suggest that 
the inclusion of a C8 substituent decreases the binding of the drugs to the enzyme, rather 
than positioning the drugs in a way that allows them to bind but not enhance cleavage. 
This is opposite of the effect seen with the C7 3’-(aminomethyl)pyrrolidinyl series (see 
Chapter VII), in which quinolones and quinazolinediones that did not enhance 
topoisomerase IIα-mediated DNA cleavage could bind to the enzyme equally as well as 
those in the series that did enhance cleavage. Results with 955-NA-dione suggest that the 
N3 amino group of the quinazolinedione core mediates some interaction with the human 
type II enzyme. This parallels the effects of the removal of the N3 substituent in the 3’-
(aminomethyl)pyrrolidinyl series. Thus, the N3 amino group plays the same role in 
quinazolinedione-enzyme interactions regardless of the structure of the C7 substituent. 
 Mutation of Met762 and Met766 of human topoisomerase IIα to the residues seen 
in B. anthracis topoisomerase IV that coordinate the water-metal ion bridge sensitizes the 
human enzyme to clinically relevant quinolones (Figure 39). CP-115,955 interacts with 
bacterial type II topoisomerases through the bridge interaction, while the C7 group 
facilitates its activity against wild-type topoisomerase IIα. To determine whether the 
introduction of a second strong interaction between CP-115,955 and the human enzyme 
would increase the activity of the compound, its ability to enhance DNA cleavage 
mediated by hTop2AM762S/M766E was assessed. The levels of cleavage induced by CP-
115,955 in the presence of wild-type and mutant topoisomerase IIα were 
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indistinguishable (Figure 48). Similar results were observed with wild-type 
topoisomerase IV and the quinolones and quinazolinediones containing a C7 3’-
(aminomethyl)pyrrolidinyl group (Figure 37). 
 Although CP-115,955 did not induce higher levels of DNA cleavage mediated by 
hTop2AM762S/M766E than by wild-type topoisomerase IIα, the cleavage complexes 
established by the mutant enzyme may be more stable than those established with the 
wild-type enzyme due to the additional point of drug-enzyme interaction. Therefore, the 
persistence of cleavage complexes established by the mutant and wild-type enzymes in 
the presence of 20 µM CP-115,955 and 200 µM 955-dione was determined. With wild-
type topoisomerase IIα, drug-induced cleavage complexes were ~2.5-fold more stable 
than those formed in the absence of drugs (Figure 49). In addition, cleavage complexes 
formed by the wild-type enzyme in the presence of CP-115,955 were more stable than 
those formed in the presence of 955-dione, as the quinazolinedione was utilized at a ten-
fold higher concentration than the quinolone (Figure 49). Furthermore, 
hTop2AM762S/M766E cleavage complexes formed in the presence of CP-115,955 were ~3-
fold more stable than those formed by the wild-type enzyme in the presence of this drug, 
while there was no difference in the persistence of cleavage complexes formed by the two 
enzymes in the presence of 955-dione (Figure 49).  
 These results indicate that quinolone-induced cleavage complexes are more stable 
than quinazolinedione-induced cleavage complexes. Moreover, although the introduction 
of a second strong interaction between the enzyme and CP-115,955 (mediated by the 
M762S and M766E mutations) did not result in higher levels of cleavage complexes 
being formed, those that were established were more stable. 
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Figure 48. DNA cleavage induced by CP-115,955 with wild-type and M762S/M766E 
mutant human topoisomerase IIα. The mutant enzyme can support the water-metal ion 
bridge interaction, while the wild-type enzyme cannot. Error bars represent the standard 
deviation of at least three independent experiments. 
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Figure 49. Effects of CP-115,955 and 955-dione on the persistence of ternary enzyme-
drug-DNA cleavage complexes formed with wild-type and M762S/M766E mutant 
human topoisomerase IIα. The stability of wild-type cleavage complexes formed in the 
absence of drugs is also shown. The mutant enzyme can support the water-metal ion 
bridge interaction, while the wild-type enzyme cannot. Initial DNA cleavage-religation 
reactions were allowed to come to equilibrium and were then diluted 25-fold with DNA 
cleavage buffer. The persistence of cleavage complexes was assessed by monitoring the 
loss of double-stranded DNA breaks (linear product) over time. Cleavage at time zero 
was set to 100%. CP-115,955 was utilized at a concentration of 20 µM, and 955-dione 
was used at a concentration of 200 µM. Error bars represent the standard deviation of at 
least three independent experiments. 
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Effects of CP-115,955-based Compounds on Levels of Topoisomerase IIα-DNA Cleavage 
Complexes Formed in Human CEM Cells 
 In order to determine whether CP-115,955-based compounds can induce the 
formation of cleavage complexes in human cells, CP-115,955, 955-dione, and 955-NA-
dione were tested in CEM cells using the RADAR assay. In this assay, cells are treated 
with the compounds for 1 h and intracellular cleavage complexes are trapped by rapid 
lysis. The DNA can then be isolated by ethanol precipitation, and the amount of 
topoisomerase IIα that is covalently attached to DNA can be measured by 
immunoblotting. Etoposide was also tested as a positive control. 
 CP-115,955 and 955-dione both increased levels of topoisomerase IIα cleavage 
complexes formed in cells, while 955-NA-dione showed no ability to do so (Figure 50). 
The relative activities of these compounds in cells (CP-115,955 > 955-dione > 955-NA-
dione) reflected their abilities to induce enzyme-mediated DNA cleavage in in vitro 
cleavage assays. However, unlike extracellular observations, the activity of CP-115,955 
was significantly less than that of etoposide when tested in the cellular context. This may 
be due to the fact that the CP-115,955-based compounds were not fully soluble in the cell 
culture media. However, it is also possible that the cellular uptake and retention of 
etoposide exceeds that of the CP-115,955-based compounds. Additionally, in in vitro 
cleavage assays, etoposide induces higher levels of topoisomerase IIα-mediated single-
stranded DNA breaks than does CP-115,955. Because single- vs. double-stranded DNA 
breaks are not distinguished in the RADAR assay, this could also account for the 
difference between the two drugs in the cellular context. 
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Figure 50. Levels of drug-induced DNA cleavage mediated by topoisomerase IIα in CEM 
cells. The ability of CP-115,955, 955-dione, and 955-NA-dione to induce DNA cleavage 
by topoisomerase IIα was determined using the RADAR assay following a 1 hr 
treatment. Levels of etoposide-induced DNA cleavage are shown for comparison. The 
inset shows the ability of 100 µM 955-dione and 955-NA-dione to induce intracellular 
DNA cleavage. Error bars represent the standard error of the mean for two independent 
experiments. 
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Summary of Conclusions 
 CP-115,955 and its derivative quinolones interact with bacterial type II 
topoisomerases through the water-metal ion bridge, just as clinically relevant quinolones 
do. In contrast, these drugs interact with human topoisomerase IIα through their C7 4’-
hydroxyphenyl moiety. Therefore, this C7 group can distinguish between the bacterial 
and human type II topoisomerases and demonstrates that there are differences between 
the bacterial and human enzymes that could potentially be taken advantage of in order to 
develop quinolones that overcome target-mediated quinolone resistance without having 
cross-reactivity with the human system. In addition, quinolones tend to have higher 
activity than quinazolinediones against both bacterial and human type II topoisomerases, 
and the N3 amino group of the quinazolinediones modulates the activities of these drugs 
against both enzymes. In contrast to results with the 3’-(aminomethyl)pyrrolidinyl series 
of compounds, the addition of a C8 methyl or methoxy group decreases the activities of 
CP-115,955-based drugs against human topoisomerase IIα, primarily by decreasing drug-
enzyme interaction. The introduction of a second strong interaction between the 
quinolones and the human enzyme by the M762S and M766E mutations does not result 
in an increase in the level of cleavage induced by the drugs (as compared to the wild-type 
enzyme), but it does result in hTop2AM762S/M766E cleavage complexes being more stable 
than their wild-type counterparts. Finally, CP-115,955 and 955-dione can induce the 
formation of topoisomerase IIα cleavage complexes in CEM cells, and their relative 
activities are reflective of those observed in extracellular cleavage assays. Therefore, it 
may be possible to develop some quinolones for use as anticancer drugs and optimize 
their efficacy using in vitro cleavage and structure-activity relationship studies. 
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CHAPTER IX 
 
CONCLUSIONS 
 
 Over a period of a few decades, quinolones have transformed from a small and 
unimportant class of drugs used primarily to treat urinary tract infections to one of the 
most frequently prescribed classes of antibacterials in the world.3,4,151 Today, they are 
used to treat a wide variety of Gram-negative and Gram-positive bacterial infections. 
Unfortunately, quinolone usage is threatened by the rising occurrence of resistance, 
which has been observed in every species that is treated by this drug class.8,11,39  
 Although there are various mechanisms of quinolone resistance, the most 
common and most clinically significant form is target-mediated resistance, which arises 
as a result of point mutations in the gyrase and topoisomerase IV enzymes that are 
targeted by these drugs.18,36,37,39,49,77 The most frequent quinolone resistance mutations 
occur at a specific, highly conserved serine residue and an acidic residue located four 
positions downstream.18,36,37,39,49,77-83 The involvement of these residues in the 
development of resistance to quinolones has been known for many years, but the specific 
mechanism by which they reduce drug action was not known. The work described in this 
dissertation provides mechanistic details on the interactions between quinolones and 
topoisomerase IV and how enzyme mutations cause resistance to the drugs. Furthermore, 
it details the basis for discrimination between bacterial and human type II topoisomerases 
by the clinically relevant quinolones and outlines the roles of various drug substituents in 
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mediating interaction with and activity against the enzymes. Taken together, this 
information suggests that a “mechanistic” approach to drug discovery holds potential. 
 
Quinolone Interactions with Type II Topoisomerases 
 
Interactions of Quinolones with B. anthracis Topoisomerase IV 
 Mutations at Ser81 and Glu85 in the A subunit of B. anthracis topoisomerase IV 
are the most common alterations associated with quinolone resistance.18,36,37,39,49,77-83 As 
described in Chapter III, the GrlAE85K mutation (but not mutations at Ser81) decreases the 
catalytic DNA relaxation and DNA catenation activities of the enzyme by interfering 
with strand passage. This may explain why alteration of the serine is significantly more 
common than alteration of the acidic residue. However, the observation that mutation of 
SerPhe or Tyr does not adversely affect enzymatic activities in the absence of drug 
raises an interesting question: why is an amino acid residue in gyrase and topoisomerase 
IV that has no apparent function other than to provide sensitivity to a class of synthetic 
antibacterials so highly conserved across the bacterial kingdom? An intriguing possibility 
comes from a study on nybomycin, an antibiotic produced by Streptomyces spp. This 
compound displays little activity against S. aureus strains that express wild-type gyrase. 
However, nybomycin is active against strains that express a SerLeu quinolone-resistant 
GyrA.152 Thus, the conserved serine residue may actually represent a “resistance 
mutation” that provides protection against naturally occurring antibiotics. Studies on the 
effects of nybomycin on wild-type and quinolone-resistant mutant topoisomerase IV from 
B. anthracis could shed light on the evolutionary significance of Ser81. 
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 As described in Chapter IV, quinolones increase the level of double-stranded 
DNA breaks generated by topoisomerase IV by stabilizing covalent enzyme-cleaved 
DNA complexes and inhibiting enzyme-mediated DNA religation. The GrlAS81F, 
GrlAS81Y, GrlAE85K, and GrlAV96A mutations decrease quinolone potency, such that 
appreciable levels of enzyme-mediated DNA cleavage can only be achieved at high drug 
concentrations. Thus, it may be possible to overcome quinolone resistance by designing a 
drug that has stronger and/or more interactions with the enzyme. In addition, these 
mutations decrease the stability of quinolone-induced cleavage complexes and decrease 
the ability of quinolones to inhibit enzyme-mediated DNA religation. It appears that 
quinolone potency correlates with cleavage complex stability and the ability of the drug 
to inhibit religation. Therefore, a drug that interacts more strongly with the mutant 
enzymes will likely also regain the ability to form stable cleavage complexes and inhibit 
DNA religation. 
 Quinazolinediones have previously been shown to overcome resistance caused by 
mutations at the serine or acidic residues.91-93,105,107,122-124 Presumably, these compounds 
do not depend on these residues for interaction with the enzyme. Accordingly, 8-methyl-
3’-(AM)P-dione maintained the ability to enhance enzyme-mediated DNA cleavage at 
low drug concentrations, even in the presence of the mutations that caused resistance to 
the quinolones. In addition, this compound was able to form stable cleavage complexes 
and inhibit DNA religation in the presence of the enzymes that were tested. Therefore, 
the quinazolinedione drug class could potentially be developed for use in the clinic to 
combat quinolone-resistant bacterial infections. 
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 A recent crystallographic study suggested that the main interaction between 
quinolones and bacterial type II topoisomerases is mediated through a bridging divalent 
metal ion.43 Chapter V describes the functional evidence supporting the existence of this 
“water-metal ion bridge” and its importance in quinolone-topoisomerase interactions.  
 In the presence of alternative metal ions, a quinazolinedione, but not a quinolone, 
could induce DNA cleavage mediated by wild-type B. anthracis topoisomerase IV. This 
shows that quinolone function requires the presence of a divalent metal ion. Mutation of 
Ser81 or Glu85 restricted the variety of metal ions that could support quinolone (but not 
quinazolinedione) activity, indicating that these residues play important roles in 
mediating quinolone-enzyme interaction. Finally, higher levels of Mg2+ were required to 
support maximal quinolone-induced (but not quinazolinedione-induced) DNA cleavage 
in the presence of GrlAS81F, GrlAS81Y, and GrlAE85K topoisomerase IV than in the 
presence of the wild-type enzyme. In contrast, GrlAV96A topoisomerase IV required wild-
type levels of Mg2+ to achieve maximal DNA cleavage in the presence of both the 
quinolone and the quinazolinedione. These results demonstrate that mutation of the 
amino acid residues that anchor the bridge decreases the affinity of Mg2+ for the 
interaction. GrlAS81F/E85K topoisomerase IV was fully resistant to ciprofloxacin, but 
sensitive to 8-methyl-3’-(AM)P-dione, and the quinolone could not compete with the 
quinazolinedione for interaction with the enzyme. Thus, quinolones interact with 
bacterial type II topoisomerases primarily through a single, strong interaction facilitated 
by the conserved serine and acidic residues.  
 Taken together, these findings support the existence of the water-metal ion bridge, 
indicate that it is the primary interaction between the drug and the enzyme, and identify 
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the serine and acidic residues as the protein anchors of the bridge. The significance of the 
water-metal ion bridge interaction, which is facilitated by the quinolone core, to drug 
activity may explain how these drugs can tolerate structural diversity of the N1, C7, and 
C8 substituents. Moreover, these results provide evidence that the most common forms of 
target-mediated resistance (i.e., mutations of the serine and acidic residue) cause 
quinolone resistance through a common mechanism – the disruption of the water-metal 
ion bridge. Therefore, at least in theory, it should be possible to overcome most instances 
of target-mediated resistance by designing a quinolone or quinolone-like drug that no 
longer depends on the water-metal ion bridge for its primary interaction with gyrase or 
topoisomerase IV.  
 
Interactions of Quinolones with E. coli Topoisomerase IV 
 Chapter VI describes the characterization of wild-type, ParCS80L, and ParCE84K 
topoisomerase IV from E. coli. Similar to results with Ser81 mutants from B. anthracis, 
the ParCS80L mutation does not adversely affect the catalytic or cleavage activities of the 
enzyme. The ParCE84K mutation has previously been shown to have a decreased catalytic 
ability.117 Presumably, this mutant enzyme (like the GrlAE85K mutant from B. anthracis) 
has a defect in strand passage. Unexpectedly, ParCE84K showed a decreased ability (~50% 
that of wild-type) to cleave DNA in the absence of drugs. Thus, this may partially 
account for the level of quinolone resistance conferred by the Glu84Lys mutation.  
 The Ser80Leu and Glu84Lys mutations caused quinolone resistance by 
decreasing not only drug potency but also drug efficacy. Although the resistance profiles 
varied somewhat from those seen with B. anthracis topoisomerase IV, the mutations still 
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had little effect on the activity of 8-methyl-3’-(AM)P-dione, suggesting that a drug that 
overcomes resistance in one species will also maintain activity against other quinolone-
resistant bacterial strains.  
 The ParCE84K mutation completely abolished ciprofloxacin activity against the 
enzyme by significantly decreasing the ability of the drug to interact with the mutant 
protein. Topoisomerase IV has been shown to be the secondary cellular target for 
quinolones in E. coli.46 Thus, the enzyme may have some intrinisic level of resistance 
that makes it a poorer target than gyrase in the bacterial cell. This could account for the 
Ser80 and Glu84 mutations having a more devastating effect on quinolone sensitivity in 
vitro than the equivalent mutations do on the sensitivity of B. anthracis topoisomerase IV 
to quinolones in vitro. 
 As observed with B. anthracis topoisomerase IV, ParCS80L required higher 
concentrations of Mg2+ than did the wild-type enzyme to achieve maximal levels of 
ciprofloxacin-induced, but not quinazolinedione-induced, DNA cleavage. These results 
indicate that the water-metal ion bridge is the major point of interaction between 
quinolones and E. coli topoisomerase IV. Thus, the bridge interaction could potentially 
be a universal mechanism for the binding of quinolones with bacterial type II 
topoisomerases. This suggests that a quinolone or quinolone-like drug that can overcome 
these mutations and maintain activity against quinolone-resistant strains will not be 
species-specific and could be useful in treating a wide range of bacterial infections. 
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Interactions of Quinolones with Human Topoisomerase IIα 
 As described in Chapter VII, human type II topoisomerases lack the amino acid 
residues necessary to coordinate the water-metal ion bridge. Thus, clinically relevant 
quinolones do not have activity against these enzymes because they lack the ability to 
form necessary binding interactions.  
 As described in Chapter VIII, some experimental quinolones have very high 
activity against human type II topoisomerases that actually exceeds that of the anticancer 
drug etoposide. CP-115,955 and related compounds, which contain a C7 4’-
hydroxyphenyl group, display high activity against the human enzyme because the C7 
group facilitates a specific interaction between the drug and the protein. The addition of a 
substituent at C8 and/or changing from a quinolone core to a quinazolinedione core 
decreased the activity of the compounds against this enzyme by decreasing their ability to 
bind with the enzyme. The presence of a C8 substituent could have this effect by altering 
the planarity and/or electronics of the drug. It is also possible that there are spatial 
constraints in the region of the enzyme where the C7 group interacts so that the enzyme 
cannot physically facilitate the presence of a group at the C8 position. There are two 
possible explanations for quinolones having higher activity than their quinazolinedione 
counterparts. The quinolone core could mediate a weak, non-bridge interaction between 
the drug and the enzyme, or a portion of the quinazolinedione core could sterically clash 
with the enzyme due to spatial constraints.  
 Although CP-115,955 did not induce higher than wild-type levels of DNA 
cleavage mediated by hTop2AM762S/M766E, the cleavage complexes formed by the mutant 
enzyme were more stable than those formed by wild-type topoisomerase IIα in the 
141 
 
presence of this drug. Therefore, it appears that multiple strong drug-enzyme interactions 
do not enhance the induction of DNA cleavage, but they do prolong the half-life of the 
DNA breaks that are generated. Presumably, drugs that induce cleavage complexes with 
longer half-lives would be more cytotoxic due to the increased likelihood of the 
complexes being transformed into permanent DNA strand breaks. 
 The abilities of CP-115,955, 955-dione, and 955-NA-dione to induce DNA 
cleavage in cultured human cells reflected the relative activities of the drugs against the 
human type II enzyme in vitro. Thus, it may possible to develop certain quinolones for 
use as anticancer chemotherapeutics. In addition, it appears that optimization of the 
substituents for interaction with and activity against the human enzymes can be based on 
in vitro cleavage assays. 
 
Overcoming Quinolone Resistance 
 Mutations in gyrase and topoisomerase IV are the most common cause of high-
level quinolone resistance.18,36,37,39,49,77 Therefore, the development of novel quinolones 
or quinolone-like drugs that retain activity against these mutated enzymes has the 
potential to greatly extend the clinical efficacy of the quinolone drug class. The initial 
hurdle to the development of drugs against resistant gyrase and topoisomerase IV was the 
concept that it would be impractical to design quinolones against every common 
mutation. This concept was based on the assumption that different mutations caused 
resistance by different mechanisms. However, as discussed in Chapters V and VI, the 
vast majority of clinically relevant mutations cause quinolone resistance through a 
common mechanism, namely by disrupting the water-metal ion bridge.  
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 As described in Chapter VII, some quinazolinediones maintain activity against 
quinolone-resistant topoisomerase IV enzymes. However, their activity is due to the 
structure of their C7 groups, not the drug core interacting with the protein independently 
of the water-metal ion bridge. Although the quinazolinediones, as a whole, may be a 
weaker drug class than the quinolones, they could be a useful platform in the laboratory 
for substituent optimization. If a quinazolinedione is identified that has high activity 
against the bacterial enzymes, its substituents could be transferred to the quinolone core 
to generate a drug with multiple strong protein interactions. Such a drug could be more 
difficult for a bacterium to evolve resistance against because the organism would likely 
require at least two simultaneous mutations (rather than sequential accumulation) to 
survive and generate an infection with a clinically significant level of resistance. 
 Human type II topoisomerases are not sensitive to the clinically relevant 
quinolones because these enzymes cannot facilitate the water-metal ion bridge 
interaction. However, they are sensitive to some experimental quinolones, including CP-
115,955, due to interactions formed between the C7 4’-hydroxyphenyl group and the 
enzyme. Therefore, in the context of quinolone interactions, the human enzymes are 
similar to mutant quinolone-resistant topoisomerase IV enzymes. For this reason, the C7 
group of quinolones and quinazolinediones can mediate interactions with both quinolone-
resistant topoisomerase IV and wild-type human topoisomerase IIα and cause undesirable 
cross-reactivity. Thus, it may be difficult to identify a C7 moiety that selectively targets 
the resistant bacterial enzymes. Notably, however, the C8 and N3 substituents can 
modulate activity of the drugs against the human enzyme while having little effect on 
activity against the bacterial enzymes. Therefore, a key to designing a clinically relevant 
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drug that overcomes quinolone resistance may be identifying C8 substituents that can be 
tolerated by the bacterial enzymes but not the human enzymes. (Figure 44 outlines the 
roles of quinolone and quinazolinedione substituents in mediating drug binding and 
function against bacterial and human type II topoisomerases.) Three compounds – 8-H-
3’-(AMP)-FQ, 8-H-3’-(AM)P-dione, and 8-methyl-3’-(AM)P-NA-dione – have been 
identified that overcome quinolone resistance in B. anthracis topoisomerase IV without 
having cross-reactivity with human topoisomerase IIα. However, these compounds still 
bind to the human enzyme as well as the compounds that did enhance enzyme-mediated 
DNA cleavage. Thus, they could have undesirable effects on the activity of the human 
type II topoisomerases in the cellular context. If this is the case, these compounds can be 
used as the starting point for further drug discovery aimed at overcoming the most 
common forms of quinolone resistance seen in bacterial infections. For example, the use 
of a tricyclic drug core, like that of levofloxacin, may provide selectivity for the bacterial 
enzymes. Therefore, the combination of a tricyclic core with the 3’-
(aminomethyl)pyrrolidinyl C7 group may generate a drug that overcomes quinolone 
resistance without binding to the human enzyme. 
 As discussed in Chapter VIII, the C7 4’-hydroxyphenyl group of CP-115,955 (and 
derivative quinolones and quinazolinediones) facilitates strong interactions with human 
topoisomerase IIα but not with wild-type or quinolone-resistant mutant B. anthracis 
topoisomerase IV. These findings demonstrate that there are differences between the 
human and bacterial enzymes that can be sensed by the C7 substituent of the drugs. Thus, 
it should be possible to identify C7 (or other) substituents that can selectively target the 
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bacterial type II topoisomerases and maintain activity against quinolone-resistant mutant 
enzymes. Overall, a mechanistic approach to drug development appears valid. 
 
Future Directions 
 After parallel studies with B. anthracis gyrase have been completed, the effects of 
quinolones and quinazolinediones on intracellular levels of type II topoisomerase-
mediated DNA cleavage can be assessed. Some compounds tested in Chapter VII not 
only induced high levels of double-stranded DNA breaks, but also induced high levels 
single-stranded DNA breaks (not shown). It is expected that single-stranded DNA breaks 
can contribute to the induction of DNA damage response pathways and aid in 
fragmentation of the genome. Thus, studies with bacterial cultures can also be used to 
determine the relative importance of double-stranded vs. single-stranded DNA breaks in 
cell kill and whether the in vitro ability of drugs to induce double- and/or single-stranded 
DNA cleavage correlates with their cellular toxicity. In addition, the ability of quinolones 
to kill bacterial cells under altered metal ion conditions could provide insight into 
quinolone function in the human body and how patient physiology could impact and alter 
drug efficacy from person to person. Cellular studies can also inform on whether/how 
mutations in the type II enzymes affect their expression levels and cellular concentrations 
and which enzyme (gyrase or topoisomerase IV) is the primary target of various 
quinolones. These studies may also shed light on why the serine and acidic residues that 
anchor the water-metal ion bridge are so highly conserved across bacterial species. Based 
on results in Chapter III, the acidic residue is important for catalytic activity. The serine 
residue, on the other hand, does not appear to be important for the cleavage or catalytic 
145 
 
abilities of the enzyme, but may be important for resistance to natural antibiotics (such as 
nybomycin). However, these mutations may have effects on the enzyme or bacterial cell 
growth that are not apparent in the in vitro assays used in this work.  
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